,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,75322,3779,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,75322,3779,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,75322,3779,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,75322,3779,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,75322,3779,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,75322,3779,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,192,1,1,,75322,3779,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
7,248,1,1,,75322,3779,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
8,256,1,1,,75322,3779,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
9,747,1,1,,24715029,3779,Unspecified,4885617.0,6783.0,,,Basic StarGazer Assay on Human SULT1E1,Other,,
10,880,2,1,,26752240,3779,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
11,880,2,1,,26752240,3779,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
12,1030,2,1,,26752240,3779,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
13,1195,1,2,,48416134,3779,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
14,1457,1,1,,26752240,3779,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
15,1458,1,1,,26752240,3779,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
16,1460,1,3,,26752240,3779,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
17,1463,1,1,,26752240,3779,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
18,1468,1,1,,26752240,3779,Inconclusive,92096784.0,4137.0,7.9433,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
19,1469,1,1,,26752240,3779,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
20,1471,2,1,,26752240,3779,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
21,1477,1,1,,26752240,3779,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
22,1479,1,2,,26752240,3779,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
23,1487,1,1,,26752240,3779,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
24,1490,2,1,,26752240,3779,Inconclusive,10954339.0,,79.4328,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
25,1688,1,1,,26752240,3779,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
26,1766,1,1,,26752240,3779,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
27,1766,1,1,,26752240,3779,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
28,1768,1,1,,26752240,3779,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
29,1768,1,1,,26752240,3779,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
30,1865,1,1,,26752240,3779,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
31,2062,1,2,,85209638,3779,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
32,2101,1,1,,26752240,3779,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
33,2107,1,1,,26752240,3779,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
34,2112,1,1,,26752240,3779,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
35,2517,2,1,,26752240,3779,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
36,2528,1,2,,26752240,3779,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
37,2546,1,1,,26752240,3779,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
38,2549,1,1,,26752240,3779,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
39,2551,1,1,,26752240,3779,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
40,2660,1,1,,90340610,3779,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
41,2666,1,1,,90340610,3779,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
42,2667,1,1,,90340610,3779,Inconclusive,4826730.0,2475.0,18.4927,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
43,2668,1,1,,90340610,3779,Active,4826730.0,2475.0,13.0918,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
44,22293,4,4,,104234147,3779,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
45,26304,4,4,,104234147,3779,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
46,29359,3,3,,104234147,3779,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
47,29811,4,3,,104234147,3779,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
48,33132,9,2,,104234147,3779,Unspecified,,,100.0,IC50,"Inhibitory concentration required for displacement of Alpha adrenergic receptor specific ligand, 2-[ [ [(2,6-dimethoxyphenoxy) ethyl]amino]methyl]benzodioxan ([3H]WB-4101) from rat brain cerebral cortical membranes",Confirmatory,6124637.0,
49,33255,3,7,,104234147,3779,Unspecified,,,,,Compound was tested for Alpha adrenergic receptor in isolated rat vas deferens,Other,3009812.0,
50,35810,3,7,,104234147,3779,Unspecified,,,,,Intrinsic activity against alpha-2 receptor in isolated guinea pig ileum,Other,8230093.0,
51,35811,3,7,,104234147,3779,Unspecified,,,,,Tested for alpha adrenergic activity against alpha-2 receptor from isolated guinea pig ileum,Other,8230093.0,
52,35880,3,7,,104234147,3779,Unspecified,,,,,Intrinsic activity was expressed as the ratio between maximal response elicited by compound and that elicited by full agonist NE towards Alpha-1 adrenergic receptor of isolated rat vas deferens,Other,1313109.0,
53,35920,7,1,,104234147,3779,Active,,,21.0,Ki,Tested for binding affinity against alpha-2 adrenergic receptor in rat brain using [3H]- rauwolscine as radioligand,Confirmatory,8230093.0,
54,36050,3,7,,104234147,3779,Unspecified,,,,,Compound was evaluated for alpha adrenoceptor agonistic activity towards Alpha-2 adrenergic receptor of isolated guinea pig ileum,Other,1313109.0,
55,36177,3,7,,104234147,3779,Unspecified,,,,,Intrinsic activity was expressed as the ratio between maximal response elicited by compound and that elicited by full agonist NE towards Alpha-2 adrenergic receptor of isolated guinea pig ileum,Other,1313109.0,
56,36448,7,1,,104234147,3779,Active,,,35.5,Ki,Tested for binding affinity against alpha-1 adrenergic receptor in rat brain using [3H]-Prazosin as radioligand,Confirmatory,8230093.0,
57,36449,3,8,,104234147,3779,Unspecified,,,,,Intrinsic activity against alpha-1 receptor in isolated rat vas deferens,Other,8230093.0,
58,36450,3,8,,104234147,3779,Unspecified,,,,,Tested for alpha adrenergic activity against alpha-1 receptor from isolated rat vas deferens,Other,8230093.0,
59,37106,7,1,,104234147,3779,Active,,,21.0,Ki,Compound was evaluated for alpha adrenergic binding affinity towards Alpha-2 adrenergic receptor of rat brain,Confirmatory,1313109.0,
60,37155,3,7,,104234147,3779,Unspecified,,,,,Intrinsic activity was expressed as the ratio between maximal response elicited by compound and that elicited by full agonist NE towards alpha 1 receptor of isolated rat vas deferens,Other,1313109.0,
61,37462,7,1,,104234147,3779,Active,,,35.5,Ki,Compound was evaluated for alpha adrenergic binding affinity towards alpha-1 receptor of rat brain,Confirmatory,1313109.0,
62,39965,3,7,,104234147,3779,Unspecified,,,,,Inhibitory activity against beta-1 adrenergic receptor in guinea pig atria is determined,Other,8230093.0,
63,39966,3,6,,104234147,3779,Unspecified,,,,,Intrinsic activity was expressed as the ratio between maximal response elicited by compound and that elicited by full agonist ISO towards Beta-1 adrenergic receptor of isolated guinea pig atria,Other,1313109.0,
64,40267,3,6,,104234147,3779,Unspecified,,,,,Intrinsic activity expressed as the percentage of maximal analogue response relative to the maximal response(100%) of isoproterenol against human beta-1-adrenoceptor using cAMP-RIA assay,Other,10377236.0,
65,40387,3,7,,104234147,3779,Unspecified,,,,,Drug concentration which produces cAMP response equal to 50% of its maximal response against human beta-1-adrenoceptor in chinese hamster ovary cells was determined,Other,10377236.0,
66,40389,4,1,,104234147,3779,Active,,,1.58489,Ki,Binding Affinity against human Beta-1 adrenergic receptor expressed in Chinese hamster ovary(CHO) cells was measured by using [125I]ICYP radioligand,Confirmatory,10377236.0,
67,40397,4,9,,104234147,3779,Active,114754.0,24925.0,,,Mean concentration required to increase basal rate of rat atria by 20 beats per minute,Other,12502364.0,
68,40402,9,1,,104234147,3779,Active,,,0.6,IC50,Compound was evaluated for its binding affinity towards beta-1 adrenergic receptor in rat heart membrane by displacing [125I]- iodocyanopindolol,Confirmatory,1354264.0,
69,40409,7,1,,104234147,3779,Active,,,0.08,Ki,Compound was evaluated for beta adrenergic binding affinity towards Beta-1 adrenergic receptor of rat brain,Confirmatory,1313109.0,
70,40414,9,2,,104234147,3779,Active,,,0.67,Ki,Compound was evaluated for the inhibition of binding of [3H]dihydroalprenolol from beta-1 adrenergic receptor of rat cerebral cortical membranes,Confirmatory,1672155.0,
71,40415,7,1,,104234147,3779,Active,,,0.08,Ki,Tested for binding affinity against beta-1 adrenergic receptor in rat brain using [3H]-CGP- 26505 as radioligand,Confirmatory,8230093.0,
72,40416,6,3,,104234147,3779,Active,,,32.0,Km,Evaluated for the affinity in stimulating cAMP synthesis by beta-1 adrenergic receptor in rat cerebral cortex.,Confirmatory,2999409.0,
73,40529,4,6,,104234147,3779,Unspecified,,,,,Agonistic activity for Beta-1 adrenergic receptor was estimated from it's chronotropic effect on rat atria,Other,12502364.0,
74,40685,7,2,,104234147,3779,Active,,,0.11,Ki,Compound was evaluated for beta adrenergic binding affinity towards beta-2 receptor of bovine lung,Confirmatory,1313109.0,
75,40686,3,7,,104234147,3779,Unspecified,,,,,Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA),Other,2993621.0,
76,40692,7,2,,104234147,3779,Active,,,0.11,Ki,Tested for binding affinity against beta-2 adrenergic receptor in bovine lung using [3H]DHA as radioligand,Confirmatory,8230093.0,
77,40694,10,1,,104234147,3779,Active,,,0.33,Kd,Affinity for cow beta-2 adrenergic receptor by measuring displacement (-)-[3H]dihydroalprenolol (DHA),Confirmatory,2993621.0,
78,40850,3,11,,104234147,3779,Unspecified,81914759.0,100722663.0,,,Intrinsic activity as ratio between maximal response compared to full agonist ISO at beta 2 receptor of isolated guinea pig tracheal strip,Other,1313109.0,
79,40861,3,10,,104234147,3779,Unspecified,81914759.0,100722663.0,,,Inhibitory activity against beta-2 adrenergic receptor in guinea pig tracheal strip is determined,Other,8230093.0,
80,41013,3,11,,104234147,3779,Unspecified,81914759.0,100722663.0,,,Compound was evaluated for beta adrenoceptor agonistic activity towards beta 2 receptor of isolated guinea pig tracheal strip,Other,1313109.0,
81,41016,3,10,,104234147,3779,Unspecified,81914759.0,100722663.0,,,Inhibitory activity against beta-2 adrenergic receptor in guinea pig tracheal strip is determined,Other,8230093.0,
82,41160,6,3,,104234147,3779,Active,,,0.03,EC50,Evaluated for Beta adrenergic receptor agonistic property in isolated guinea pig atria,Confirmatory,6124637.0,
83,41166,3,6,,104234147,3779,Unspecified,,,,,Evaluated for the efficacy in stimulating cAMP synthesis by beta-2 adrenergic receptor in human platelets,Other,2999409.0,
84,41296,3,7,,104234147,3779,Unspecified,,,,,Intrinsic activity against beta adrenergic receptor in isolated guinea pig atria,Other,3009812.0,
85,41297,3,7,,104234147,3779,Unspecified,,,,,Intrinsic activity against beta adrenergic receptor in isolated guinea pig tracheal strip,Other,3009812.0,
86,41313,3,7,,104234147,3779,Unspecified,,,,,Compound was tested for beta adrenergic receptor activity in isolated guinea pig atria,Other,3009812.0,
87,41314,3,7,,104234147,3779,Unspecified,,,,,Compound was tested for beta adrenergic receptor activity in isolated guinea pig tracheal strip,Other,3009812.0,
88,41324,3,6,,104234147,3779,Unspecified,,,,,Intrinsic activity expressed as the percentage of maximal analogue response relative to the maximal response(100%) of isoproterenol against human beta-2-adrenoceptor,Other,10377236.0,
89,41335,6,3,,104234147,3779,Active,,,0.05,Km,Evaluated for the affinity in stimulating cAMP synthesis by beta-2-adrenoceptor in human platelets.,Confirmatory,2999409.0,
90,41341,3,7,,104234147,3779,Unspecified,,,,,Drug concentration which produces cAMP response equal to 50% of its maximal response against human beta-2-adrenoceptor in chinese hamster ovary cells was determined,Other,10377236.0,
91,41344,4,1,,104234147,3779,Active,,,0.67608,Ki,Binding Affinity against human beta-2 adrenergic receptor expressed in Chinese hamster ovary(CHO) cells was measured by using [125I]ICYP radioligand,Confirmatory,10377236.0,
92,41445,6,3,,104234147,3779,Active,,,0.98,EC50,Effective concentration against 125I]iodocyanopindolol(ICYP) binding to beta adrenergic receptor was determined,Confirmatory,2859372.0,
93,41472,9,1,,104234147,3779,Active,,,1.0,IC50,Compound was evaluated for its binding affinity towards beta-2 adrenergic receptor in rat soleus membrane by displacing (-)-isoproterenol (50 uM),Confirmatory,1354264.0,
94,41474,9,2,,104234147,3779,Active,114768.0,24176.0,0.0001,IC50,Inhibition of spontaneous contractions in isolated rat uterus,Confirmatory,12502364.0,
95,41484,7,1,,104234147,3779,Active,,,0.0001,IC50,Agonistic activity for Beta-2 adrenergic receptor was assessed by it's inhibitory effect on spontaneous contractions in isolated rat uterus,Confirmatory,12502364.0,
96,41513,4,6,,104234147,3779,Active,,,0.087,EC50,Concentration required to effect a 50% relaxation of rat ferret detrusor basal tone,Confirmatory,12502364.0,
97,41601,4,6,,104234147,3779,Active,,,0.006999999999999999,EC50,Beta adrenergic receptor agonistic activity for the stimulation of accumulation of cyclic AMP in cultured C6 glioma cells,Confirmatory,1672155.0,
98,41608,9,2,,104234147,3779,Active,,,0.1,IC50,Inhibitory concentration required for displacement of Beta adrenergic receptor specific ligand [3H]dihydroalprenolol from rat brain cerebral cortical membranes,Confirmatory,6124637.0,
99,41634,5,1,,104234147,3779,Active,,,0.0871,EC50,Agonistic activity for Beta-3 adrenergic receptor as relaxing ability of isolated ferret detrusor basal tone,Confirmatory,12502364.0,
100,41660,7,6,,104234147,3779,Active,461604.0,155.0,1.0,EC50,Agonist efficacy for human Beta-3 adrenergic receptor expressed in chinese hamster ovary cells,Confirmatory,,
101,41800,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Agonist activity at human Beta-3 adrenergic receptor relative to isoprenaline,Other,,
102,41884,7,1,,104234147,3779,Active,,,0.325,IC50,The compound was evaluated for the inhibition of [125I]cyanopindolol binding to beta adrenergic receptor in rat reticulocyte membrane.,Confirmatory,2887658.0,
103,41917,3,6,,104234147,3779,Unspecified,,,,,Intrinsic activity expressed as the percentage of maximal analogue response relative to the maximal response(100%) of isoproterenol against human beta-3-adrenoceptor using cAMP-RIA assay,Other,10377236.0,
104,41933,3,6,,104234147,3779,Unspecified,,,,,Drug concentration which produces cAMP response equal to 50% of its maximal response against human beta-3-adrenoceptor expressed in chinese hamster ovary cells was determined,Other,10377236.0,
105,41935,4,1,,104234147,3779,Active,,,18.6209,Ki,Binding Affinity against human Beta-3 adrenergic receptor expressed in Chinese hamster ovary(CHO) cells was measured by using [125I]ICYP radioligand,Confirmatory,10377236.0,
106,41937,4,7,,104234147,3779,Unspecified,,,63.0,EC50,Activity for beta 3-adrenoceptor was assessed from effect on stimulation of lipolysis in rat adipocytes.,Confirmatory,7562902.0,
107,41939,6,3,,104234147,3779,Active,,,0.013000000000000001,EC50,In vitro beta adrenergic receptor activity against beta-3 adrenergic receptor in rat epididymal fat pads by stimulation of glycerol release from adipocytes.,Confirmatory,1354264.0,
108,41943,7,4,,104234147,3779,Unspecified,,,,,Dose necessary to produce 50% of the isoprenaline effect to inhibit GDP binding to beta-3 adrenergic receptor in brown adipose tissue (BAT mitochondria) of rats after subcutaneous administration.,Other,1350309.0,
109,42047,5,2,,104234147,3779,Active,,,0.006,EC50,Agonistic activity (beta-1 adrenergic receptor) for the percent maximal increase in contraction rate of isolated guinea pig atria,Confirmatory,1672155.0,
110,42183,3,6,,104234147,3779,Unspecified,,,,,Compound was evaluated for beta adrenoceptor agonistic activity towards Beta-1 adrenergic receptor of isolated guinea pig atria,Other,1313109.0,
111,42202,3,7,,104234147,3779,Unspecified,,,,,Intrinsic activity against beta-1 adrenergic receptor in isolated guinea pig atria,Other,8230093.0,
112,44396,3,6,,104234147,3779,Unspecified,,,,,concentration-response expressed as a percent of the maximal response to R-(-) isoproterenol (ISO),Other,11806709.0,
113,44399,4,1,,104234147,3779,Active,,,0.001,EC50,"Activity against human beta 1 adrenergic receptor (AR), expressed in CHO cells.",Confirmatory,11806709.0,
114,44414,3,6,,104234147,3779,Unspecified,,,,,concentration-response expressed as a percent of the maximal response to R-(-) isoprenaline (ISO),Other,11806709.0,
115,44542,4,1,,104234147,3779,Active,,,0.00015800000000000002,EC50,"Activity against human beta 2 adrenergic receptor (AR), expressed in CHO cells",Confirmatory,11806709.0,
116,44545,5,6,,104234147,3779,Active,81914759.0,100722663.0,0.057999999999999996,EC50,Agonistic activity (beta2- adrenergic) for the percent maximal relaxation of isolated guinea pig trachea,Confirmatory,1672155.0,
117,44566,3,6,,104234147,3779,Unspecified,,,,,concentration-response expressed as a percent of the maximal response to R-(-) isoproterenol (ISO),Other,11806709.0,
118,44570,4,1,,104234147,3779,Active,,,0.00316,EC50,"Activity against human beta 3 adrenergic receptor (AR), expressed in CHO cells.",Confirmatory,11806709.0,
119,56242,3,3,,104234147,3779,Unspecified,,,,,Cardiovascular activity (blood pressure) (0.31 ug/kg) in dog before beta-blockade,Other,2864447.0,
120,56243,3,3,,104234147,3779,Unspecified,,,,,Cardiovascular activity (blood pressure) (0.31 ug/kg)in dog after beta-blockade,Other,2864447.0,
121,56244,3,3,,104234147,3779,Unspecified,,,,,Cardiovascular activity (contractility) (0.31 ug/kg) in dog after beta-blockade,Other,2864447.0,
122,56245,3,3,,104234147,3779,Unspecified,,,,,Cardiovascular activity (contractility) (0.31 ug/kg) in dog before beta-blockade.,Other,2864447.0,
123,56246,3,4,,104234147,3779,Unspecified,,,,,Cardiovascular activity (heart rate) (0.31 ug/kg) in dog after beta-blockade.,Other,2864447.0,
124,56247,3,4,,104234147,3779,Unspecified,,,,,Cardiovascular activity (heart rate) (0.31 ug/kg) in dog before beta-blockade,Other,2864447.0,
125,57843,3,4,,104234147,3779,Unspecified,,,,,Cardioselectivity expressed as change in blood pressure for 100% increase in right ventricular contractile force in dogs,Other,7277389.0,
126,57846,3,4,,104234147,3779,Unspecified,,,,,Cardioselectivity expressed as change in blood pressure for 50% increase in right ventricular contractile force in dogs,Other,7277389.0,
127,58655,6,1,,104234147,3779,Unspecified,,,,,Ionotropic selectivity expressed as change in heart rate for 100 percent increase in right ventricular contractile force in dogs,Other,7277389.0,
128,58658,6,1,,104234147,3779,Unspecified,,,,,Ionotropic selectivity expressed as change in heart rate for 50 percent increase in right ventricular contractile force in dogs,Other,7277389.0,
129,59285,3,4,,104234147,3779,Unspecified,,,,,"Compound was tested in anesthetized dogs for increase in heart rate (equipotent dose at ED25) Mean ED25 value, obtained at a dose of 0.021 ug/kg",Other,6453996.0,
130,59374,3,4,,104234147,3779,Unspecified,,,,,"Intrinsic sympathomimetic activity (ISA, calculated as the percent of maximum change in heart rate (HR)",Other,6115058.0,
131,59375,3,3,,104234147,3779,Unspecified,,,,,"Intrinsic sympathomimetic activity (ISA), calculated as the percent of maximum change in hind limb perfusion pressure (HLPP)",Other,6115058.0,
132,59640,6,2,,104234147,3779,Unspecified,,,,,"Compound was tested in anesthetized dogs for inhibition of bronchoconstriction (equipotent dose at ED50) Mean ED50 value, obtained at a dose of 0.054 ug/kg",Other,6453996.0,
133,59673,6,3,,104234147,3779,Unspecified,,,,,Effective dose required for the maximum heart rate in anesthetized dogs.,Other,6115058.0,
134,59674,6,2,,104234147,3779,Unspecified,,,,,Effective dose required for the maximum hind limb perfusion pressure(HLPP) in anesthetized dogs.,Other,6115058.0,
135,59952,3,3,,104234147,3779,Unspecified,,,,,"The change in cardiac contractile force was determined after 0.1 mg/kg iv administration with 0.5 mg/kg, iv propranolol in dog (p<0.05)",Other,7154009.0,
136,59953,3,3,,104234147,3779,Unspecified,,,,,The change in cardiac contractile force was determined after 0.1 ug/kg iv administration in dog.,Other,7154009.0,
137,59969,3,4,,104234147,3779,Unspecified,,,,,"The change in mean arterial blood pressure was determined after 0.1 mg/kg iv administration with 0.5 mg/kg, iv propranolol in dog (p<0.05)",Other,7154009.0,
138,59970,3,4,,104234147,3779,Unspecified,,,,,The change in mean arterial blood pressure was determined after 0.1 ug/kg iv administration in dog.,Other,7154009.0,
139,60580,4,1,,104234147,3779,Unspecified,,,,,Inotropic potency expressed as 100 percent increase in right ventricular contractile force in dogs,Other,7277389.0,
140,60584,4,1,,104234147,3779,Unspecified,,,,,Inotropic potency expressed as 50 percent increase in right ventricular contractile force in dogs,Other,7277389.0,
141,70530,3,3,,104234147,3779,Unspecified,,,,,Free energy of binding to turkey erythrocyte beta receptor,Other,3005570.0,
142,73725,6,2,,104234147,3779,Active,,,0.0032,EC50,Effective concentration for increasing potency force in guinea pig isolated left atria,Confirmatory,7277389.0,
143,73727,6,2,,104234147,3779,Active,,,0.0062,EC50,Effective concentration for increasing potency rate in guinea pig isolated right atria,Confirmatory,7277389.0,
144,76783,8,1,,104234147,3779,Unspecified,,,1500000.0,ED50,Positive inotropic effect in isolated left guinea pig atria.,Confirmatory,3783604.0,
145,76809,8,1,,104234147,3779,Unspecified,,,1500000.0,ED50,Positive inotropic activity in isolated left guinea pig atria.,Confirmatory,3783603.0,
146,76919,3,4,,104234147,3779,Unspecified,,,,,Compound was tested for or relative intrinsic activity in guinea pig isolated atrium left atria,Other,7277389.0,
147,76920,3,4,,104234147,3779,Unspecified,,,,,Compound was tested for relative intrinsic activity in guinea pig isolated atrium right atria,Other,7277389.0,
148,77604,3,3,,104234147,3779,Unspecified,,,,,Maximum response compared to maximum response to isoprenaline.,Other,3783603.0,
149,77605,3,3,,104234147,3779,Unspecified,,,,,Intrinsic activity calculated as the ratio of the maximum response to the compound to the maximum response to isoprenaline.,Other,3783604.0,
150,78134,6,2,,104234147,3779,Active,,,0.15,IC50,Compound was evaluated in vitro by SDT (Schultz-Dale Test) against isolated guinea pig lung strips repeatedly challenged with antigen in the presence of an antihistamine (H1) at a concentration 30 uM.,Confirmatory,6150113.0,
151,88758,3,6,,104234147,3779,Unspecified,,,,,Agonistic potency against BETA1-AR expressed in CHO cells by using CRE-LUC assay,Other,10691685.0,
152,88760,3,6,,104234147,3779,Unspecified,,,,,Intrinsic activity against BETA2-AR expressed in CHO cells by using CRE-LUC assay,Other,10691685.0,
153,88765,3,6,,104234147,3779,Unspecified,,,,,Agonistic potency against BETA2-AR expressed in CHO cells by using CRE-LUC assay,Other,10691685.0,
154,88767,3,6,,104234147,3779,Unspecified,,,,,Intrinsic activity against Beta3-AR expressed in CHO cells by using CRE-LUC assay,Other,10691685.0,
155,88771,3,6,,104234147,3779,Unspecified,,,,,Agonistic potency against Beta3-AR expressed in CHO cells by using CRE-LUC assay,Other,10691685.0,
156,91268,3,6,,104234147,3779,Unspecified,,,,,Intrinsic activity against BETA1-AR expressed in CHO cells by using CRE-LUC assay,Other,10691685.0,
157,169094,5,2,,104234147,3779,Active,,,0.01,EC50,In vitro concentration required to produce 50% relaxation of rat detrusor,Confirmatory,11311067.0,
158,171642,3,4,,104234147,3779,Unspecified,,,,,Change in diastolic blood pressure after iv administration of 0.625 mg/kg in anesthetized rats,Other,10447956.0,
159,171675,3,4,,104234147,3779,Unspecified,,,,,Change in systolic blood pressure after iv administration of 0.625 mg/kg in anesthetized rats,Other,10447956.0,
160,174353,4,4,,104234147,3779,Unspecified,,,,,"Cyclic AMP accumulation in Rat brain cerebral cortical slices by the compound, activity expressed as % conversion",Other,3001304.0,
161,176028,4,3,,104234147,3779,Active,,,0.226,EC50,The compound was evaluated for its ability to stimulate adenylate cyclase activity,Confirmatory,2887658.0,
162,177146,6,2,,104234147,3779,Unspecified,,,,,In vivo dose required to lower the intrabladder pressure of the anesthetized rat by 50% over that before compound administration,Other,11311067.0,
163,179663,3,9,,104234147,3779,Unspecified,114754.0,24925.0,,,Evaluated for the efficacy in stimulating cAMP synthesis by beta-1 adrenergic receptor in rat cerebral cortex.,Other,2999409.0,
164,181372,3,3,,104234147,3779,Unspecified,,,,,The compound was evaluated for the intrinsic activity compared to (-)-isoproterenol.,Other,2887658.0,
165,192742,3,3,,104234147,3779,Unspecified,,,,,Maximum rate of rise of the left ventricular isovolumetric pressure was measured after iv administration of 0.625 mg/kg in anesthetized rats,Other,10447956.0,
166,193761,6,1,,104234147,3779,Unspecified,,,,,Change in heart rate after iv administration of 0.625 mg/kg in anesthetized rats,Other,10447956.0,
167,201136,3,3,,104234147,3779,Active,,,,,KA value was evaluated for the production cyclic AMP in SF-49 lymphoma cell,Other,2859372.0,
168,201138,4,1,,104234147,3779,Unspecified,,,,,KD constant value was evaluated for the displacement of ICYP (iodocyanopindolol) binding in SF-49 lymphoma cell,Other,2859372.0,
169,218845,3,7,,104234147,3779,Unspecified,,,,,Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the membranes of bovine skeletal muscle preparation,Other,2836587.0,
170,218846,3,7,,104234147,3779,Inconclusive,,,,,Compound was evaluated for change in Gibb's free energy at Low affinity beta2- adrenoceptor in the membranes of bovine skeletal muscle preparation; Not determined,Other,2836587.0,
171,218847,4,6,,104234147,3779,Unspecified,,,,,Change in Gibb's free energy at High affinity beta2- adrenoceptor in Chang living cells.,Other,2836587.0,
172,218848,4,6,,104234147,3779,Unspecified,,,,,Change in Gibb's free energy at Low affinity beta-2-adrenoceptor in the Chang living cells,Other,2836587.0,
173,219072,5,2,,104234147,3779,Active,,,0.0871,EC50,"Compound is tested for EC50, the mean concentration required to produce 50% relaxation of ferret detrusor in vitro",Confirmatory,11311067.0,
174,220909,6,3,,104234147,3779,Active,,,0.0015,EC50,In vitro beta-adrenergic activity against beta-1 adrenergic receptor by stimulation of rate of contraction of guinea pig atria,Confirmatory,1354264.0,
175,220911,6,3,,104234147,3779,Active,,,0.0053,IC50,In vitro beta-adrenergic activity against beta-1 adrenergic receptor by the inhibition of insulin stimulated [14C]- glucose incorporation into glycogen in isolated rat soleus muscle,Confirmatory,1354264.0,
176,220914,3,6,,104234147,3779,Unspecified,,,,,"Agonistic activity towards beta-1 adrenoceptor. EC20 value, which is the concentration required to increase 20 beats/minute in the rat atria",Other,11311067.0,
177,220922,5,3,,104234147,3779,Active,,,0.0001,IC50,"Agonistic activity towards beta-2 adrenoceptor. IC50, the mean concentration required to produce 50% inhibition of uterine contraction",Confirmatory,11311067.0,
178,220926,5,3,,104234147,3779,Active,,,0.0871,EC50,"Agonistic activity towards beta-3 adrenoceptor. EC50, the mean concentration required to produce 50% relaxation of detrusor before the addition in the ferret detrusor",Confirmatory,11311067.0,
179,220927,3,6,,104234147,3779,Unspecified,,,,,Activity compared to that observed following forskolin (10e -5).,Other,11311067.0,
180,229659,3,3,,104234147,3779,Unspecified,,,,,Selectivity ratio (Beta-1EC50/ Beta-3EC50),Other,11806709.0,
181,229660,3,3,,104234147,3779,Unspecified,,,,,Selectivity ratio (Beta-2EC50/ Beta-3EC50),Other,11806709.0,
182,230167,4,3,,104234147,3779,Unspecified,,,,,The intrinsic activity is given as the ratio of the maximum stimulation with forskolin (10e-5 M),Other,12502364.0,
183,234276,3,4,,104234147,3779,Unspecified,,,,,Selectivity is expressed as the ratio of ED50 on hind limb perfusion pressure to the ED50 on heart rate,Other,6115058.0,
184,234626,3,4,,104234147,3779,Unspecified,,,,,Concentration ratio of beta-3 (EC50) to beta-1 (EC50),Other,11311067.0,
185,234627,3,4,,104234147,3779,Unspecified,,,,,Concentration ratio of beta-3 (EC50) to beta2 (EC50),Other,11311067.0,
186,234915,4,3,,104234147,3779,Unspecified,,,,,Selectivity for beta3-AR over beta1-AR was determined,Other,12502364.0,
187,234917,4,3,,104234147,3779,Unspecified,,,,,Selectivity for beta3-AR over beta2-AR was determined,Other,12502364.0,
188,235309,7,1,,104234147,3779,Unspecified,543882.0,25645.0,,,"Ratio of the dose raising the rat heart rate to 500bpm, to ED50 for inhibition of GDP binding to beta-3 adrenergic receptor",Other,1350309.0,
189,246460,5,6,,104234147,3779,Active,48429211.0,153.0,8.4e-05,EC50,Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-1 adrenergic receptor,Confirmatory,15603933.0,
190,246461,5,6,,104234147,3779,Active,296439450.0,154.0,0.002,EC50,Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-2 adrenergic receptor,Confirmatory,15603933.0,
191,246462,5,6,,104234147,3779,Active,461604.0,155.0,0.0009699999999999999,EC50,Agonistic activity was assessed by measuring cAMP accumulation in CHO cell lines expressing cloned human Beta-3 adrenergic receptor,Confirmatory,15603933.0,
192,249451,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Ratio of agonistic activity to produce cAMP by stimulating beta-2 and beta-3 adrenergic receptor in chinese hamster ovary cells,Other,15603933.0,
193,249451,3,10,,104234147,3779,Unspecified,296439450.0,154.0,,,Ratio of agonistic activity to produce cAMP by stimulating beta-2 and beta-3 adrenergic receptor in chinese hamster ovary cells,Other,15603933.0,
194,252256,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Ratio of agonistic activity to produce cAMP by stimulating beta-1 and beta-3 adrenergic receptor in chinese hamster ovary cells,Other,15603933.0,
195,252256,3,10,,104234147,3779,Unspecified,48429211.0,153.0,,,Ratio of agonistic activity to produce cAMP by stimulating beta-1 and beta-3 adrenergic receptor in chinese hamster ovary cells,Other,15603933.0,
196,264374,5,1,,104234147,3779,Active,461604.0,155.0,0.00316,EC50,Activity at human beta-3 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,Confirmatory,16640337.0,
197,264375,5,1,,104234147,3779,Active,296439450.0,154.0,0.00015800000000000002,EC50,Activity at human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,Confirmatory,16640337.0,
198,264376,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Selectivity for human beta3 adrenergic receptor over beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,Other,16640337.0,
199,264376,3,10,,104234147,3779,Unspecified,296439450.0,154.0,,,Selectivity for human beta3 adrenergic receptor over beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,Other,16640337.0,
200,264377,5,1,,104234147,3779,Active,48429211.0,153.0,0.001,EC50,Activity at human beta-1 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,Confirmatory,16640337.0,
201,264378,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Selectivity for human beta-3 adrenergic receptor over beta-1 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,Other,16640337.0,
202,264378,3,10,,104234147,3779,Unspecified,48429211.0,153.0,,,Selectivity for human beta-3 adrenergic receptor over beta-1 adrenergic receptor expressed in CHO cells by stimulation of cAMP production,Other,16640337.0,
203,264432,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Activity against human beta-3 adrenergic receptor expressed in CHO cells by stimulation of cAMP production relative to R-(-)-isoproterenol,Other,16640337.0,
204,264433,3,10,,104234147,3779,Unspecified,296439450.0,154.0,,,Activity against human beta-2 adrenergic receptor expressed in CHO cells by stimulation of cAMP production relative to R-(-)-isoproterenol,Other,16640337.0,
205,264434,3,10,,104234147,3779,Unspecified,48429211.0,153.0,,,Activity against human beta-1 adrenergic receptor expressed in CHO cells by stimulation of cAMP production relative to R-(-)-isoproterenol,Other,16640337.0,
206,311367,3,6,,104234147,3779,Unspecified,,,,,Permeability coefficient in human skin,Other,17827020.0,
207,317595,5,6,,104234147,3779,Active,461604.0,155.0,0.0009699999999999999,EC50,Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA,Confirmatory,18307290.0,
208,317596,5,6,,104234147,3779,Active,48429211.0,153.0,8.4e-05,EC50,Agonist activity at human beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by EIA,Confirmatory,18307290.0,
209,317597,3,3,,104234147,3779,Unspecified,,,,,Ratio of EC50 for human beta3 adrenergic receptor over EC50 for human beta-1 adrenergic receptor,Other,18307290.0,
210,317598,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Intrinsic activity at human beta3 adrenergic receptor expressed in CHO cells assessed as ratio between maximal effect of drug to maximal effect of isoproterenol by EIA,Other,18307290.0,
211,317599,3,4,,104234147,3779,Inconclusive,,,,,"Ratio of Cmax for drug to Cmax for [4-(4-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-ethyl}-phenoxy)-phenoxy]-acetic acid in dog at 0.32 or 1.0 mg/kg, po by cassette assay",Other,18307290.0,
212,317600,3,4,,104234147,3779,Inconclusive,,,,,"Ratio of AUC for drug to AUC for [4-(4-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-ethyl}-phenoxy)-phenoxy]-acetic acid in dog at 0.32 or 1.0 mg/kg, po by cassette assay",Other,18307290.0,
213,326592,5,6,,104234147,3779,Active,461604.0,155.0,0.0058,EC50,Agonist activity at human adrenergic beta-3 receptor expressed in CHO cells assessed as cAMP levels by DELFIA method,Confirmatory,18083578.0,
214,326593,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Intrinsic activity at human adrenergic beta-3 receptor expressed in CHO cells assessed as cAMP levels relative to R-(-)-isoproterenol,Other,18083578.0,
215,326595,5,6,,104234147,3779,Active,461604.0,155.0,0.0039,EC50,Agonist activity at human adrenergic beta3 receptor expressed in CHO cells assessed as [3H]cAMP levels by radiolabeled ligand based assay,Confirmatory,18083578.0,
216,336963,10,1,,104234147,3779,Unspecified,,,,,Coronary dilatory activity in perfused guinea pig heart assessed as minimum effective concentration,Other,2607347.0,
217,336964,10,1,,104234147,3779,Unspecified,,,,,Cardiotropic activity in perfused guinea pig heart assessed as minimum effective concentration,Other,2607347.0,
218,337194,3,5,,104234147,3779,Active,,,,,Cardiotropic activity in perfused guinea pig heart assessed as positive ionotropy,Other,2607347.0,
219,337195,3,5,,104234147,3779,Active,,,,,Cardiotropic activity in perfused guinea pig heart assessed as positive chronotropy,Other,2607347.0,
220,344246,5,6,,104234147,3779,Active,48429211.0,153.0,8.4e-05,EC50,Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay,Confirmatory,18553954.0,
221,344247,5,6,,104234147,3779,Active,461604.0,155.0,0.0009699999999999999,EC50,Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay,Confirmatory,18553954.0,
222,344248,5,6,,104234147,3779,Active,296439450.0,154.0,0.002,EC50,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay,Confirmatory,18553954.0,
223,344249,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Intrinsic activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immuno assay relative to isoproterenol,Other,18553954.0,
224,344250,3,3,,104234147,3779,Unspecified,,,,,Selectivity ratio of EC50 for human recombinant beta-1 androgen receptor to EC50 for human recombinant beta3 androgen receptor,Other,18553954.0,
225,344251,3,3,,104234147,3779,Unspecified,,,,,Selectivity ratio of EC50 for human recombinant beta2 androgen receptor to EC50 for human recombinant beta3 androgen receptor,Other,18553954.0,
226,344252,3,4,,104234147,3779,Inconclusive,,,,,"Ratio of Cmax for drug to Cmax for 4'-{2-[(R)-2-(3-Chloro-phenyl)-2-hydroxy-ethylamino]-ethyl}-3-isopropoxy-biphenyl-4-carboxylic acid in beagle dog at 0.1 mg/kg, po by cassette assay",Other,18553954.0,
227,349760,5,6,,104234147,3779,Active,48429211.0,153.0,0.00084,EC50,Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay,Confirmatory,19366244.0,
228,349761,5,6,,104234147,3779,Active,296439450.0,154.0,0.002,EC50,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay,Confirmatory,19366244.0,
229,349762,9,2,,104234147,3779,Active,461604.0,155.0,0.0009699999999999999,EC50,Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation by enzyme immunoassay,Confirmatory,19366244.0,
230,350867,7,6,,104234147,3779,Active,48429211.0,153.0,0.1,EC50,Agonist activity at human beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,19362005.0,
231,350869,7,6,,104234147,3779,Active,296439450.0,154.0,0.003,EC50,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,19362005.0,
232,350871,7,6,,104234147,3779,Active,461604.0,155.0,0.012,EC50,Agonist activity at human beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,19362005.0,
233,366403,5,6,,104234147,3779,Active,461604.0,155.0,0.0009699999999999999,EC50,Agonist activity at human cloned beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,18651730.0,
234,366404,5,6,,104234147,3779,Active,48429211.0,153.0,8.4e-05,EC50,Agonist activity at human cloned beta-1 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,18651730.0,
235,366405,3,3,,104234147,3779,Unspecified,,,,,Ratio of EC50 for human cloned beta-1 adrenergic receptor to EC50 for human cloned beta3 adrenergic receptor,Other,18651730.0,
236,366406,5,6,,104234147,3779,Active,296439450.0,154.0,0.002,EC50,Agonist activity at human beta2 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,18651730.0,
237,366407,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Agonist activity at human cloned beta3 adrenergic receptor expressed in CHO cells assessed as cAMP accumulation relative to isoproterenol,Other,18651730.0,
238,366408,3,3,,104234147,3779,Inconclusive,,,,,"Ratio of AUC for drug to AUC for {3-[((7S)-7-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]phenoxy}acetic acid hydrochloride in dog at 0.32 or 0.2 mg/kg, po by cassette dosing assay",Other,18651730.0,
239,366409,3,3,,104234147,3779,Inconclusive,,,,,"Ratio of Cmax for drug to Cmax for {3-[((7S)-7-{[(2R)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]phenoxy}acetic acid hydrochloride in dog at 0.32 or 0.2 mg/kg, po by cassette dosing assay",Other,18651730.0,
240,386483,3,6,,104234147,3779,Unspecified,,,,,Antagonist activity at alpha2A adrenergic receptor expressed in HEK293 cells assessed as blockade of secreted alkaline phosphatase activity at 1 uM after 6 hrs relative to control,Other,18077343.0,
241,387245,5,6,,104234147,3779,Active,461604.0,155.0,0.0009699999999999999,EC50,Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,18752946.0,
242,387246,5,6,,104234147,3779,Active,48429211.0,153.0,8.4e-05,EC50,Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,18752946.0,
243,387247,3,4,,104234147,3779,Unspecified,,,,,Selectivity for human cloned adrenergic beta-1 receptor over human cloned adrenergic beta3 receptor expressed in CHO cells,Other,18752946.0,
244,391626,3,9,,104234147,3779,Unspecified,114766.0,101836719.0,,,"Selectivity ratio, Ki for adrenergic beta2 receptor to EC50 for adrenergic beta2 receptor in Syrian hamster DDT1 MF2 cells",Other,18783211.0,
245,392783,7,1,,104234147,3779,Unspecified,,,,,Binding interaction with fibrinogen assessed as spin lattice relaxation rate enumerated as normalized affinity index at given concentration and fixed temperature by NMR relaxation experiment,Other,19157885.0,
246,392784,6,1,,104234147,3779,Unspecified,,,,,Binding interaction with platelet assessed as spin lattice relaxation rate enumerated as normalized affinity index at given concentration and fixed temperature by NMR relaxation experiment,Other,19157885.0,
247,409954,4,9,,104234147,3779,Inactive,341940599.0,17161.0,,,Inhibition of mouse brain MAOA,Other,18834112.0,
248,409956,4,9,,104234147,3779,Inactive,341940629.0,109731.0,,,Inhibition of mouse brain MAOB,Other,18834112.0,
249,414891,6,6,,104234147,3779,Active,48429211.0,153.0,0.007940000000000001,EC50,Agonist activity at human cloned beta-1 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,Confirmatory,19317397.0,
250,414892,6,6,,104234147,3779,Active,296439450.0,154.0,0.039810000000000005,EC50,Agonist activity at human cloned beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,Confirmatory,19317397.0,
251,414894,6,6,,104234147,3779,Active,461604.0,155.0,0.039810000000000005,EC50,Agonist activity at human cloned beta3 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation by beta-galactosidase based whole cell assay,Confirmatory,19317397.0,
252,414900,3,7,,104234147,3779,Inactive,,,,,Agonist activity at beta-1 adrenergic receptor in guinea pig trachea assessed as inhibition of electrical stimulation-induced contraction in guinea pig trachea after 3 hrs washout,Other,19317397.0,
253,414916,6,1,,104234147,3779,Unspecified,,,5011870.0,EC50,Selectivity assessed as difference in pEC50 for human cloned beta2 adrenergic receptor and pEC50 for human cloned beta-1 adrenergic receptor,Confirmatory,19317397.0,
254,414917,6,1,,104234147,3779,Unspecified,,,1000000.0,EC50,Selectivity assessed as difference in pEC50 for human cloned beta2 adrenergic receptor and pEC50 for human cloned beta3 adrenergic receptor,Confirmatory,19317397.0,
255,420990,7,6,,104234147,3779,Active,461604.0,155.0,0.1,EC50,Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay,Confirmatory,19232786.0,
256,420991,7,6,,104234147,3779,Active,296439450.0,154.0,0.003,EC50,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay,Confirmatory,19232786.0,
257,420992,7,6,,104234147,3779,Active,48429211.0,153.0,0.012,EC50,Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay,Confirmatory,19232786.0,
258,420993,3,10,,104234147,3779,Unspecified,461604.0,155.0,,,Intrinsic activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay relative to isoproterenol,Other,19232786.0,
259,420994,3,10,,104234147,3779,Unspecified,296439450.0,154.0,,,Intrinsic activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay relative to isoproterenol,Other,19232786.0,
260,420995,3,10,,104234147,3779,Unspecified,48429211.0,153.0,,,Intrinsic activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as increase in cAMP production after 2 days by radioimmunoassay relative to isoproterenol,Other,19232786.0,
261,425695,4,6,,104234147,3779,Active,,,,,Inhibition of beta2 adrenergic receptor expressed in HEK293 cells co-transfected with PKA fragments Reg-F[1] and cat-F[2]-fused renilla luciferase assessed as effect on receptor regulated PKA activation at 1 uM after 30 mins by protein-fragment complementation assay,Other,19464886.0,
262,425696,4,6,,104234147,3779,Inactive,,,,,Inhibition of beta2 adrenergic receptor expressed in HEK293 cells co-transfected with PKA fragments Reg-F[1] and cat-F[2]-fused renilla luciferase assessed as effect on receptor regulated PKA activation at 1 uM after 30 mins by protein-fragment complementation assay in presence of inverse agonist ICI-118551,Other,19464886.0,
263,426242,12,2,,104234147,3779,Active,296439450.0,154.0,0.05,Kd,Binding affinity to human adrenergic beta2 receptor,Confirmatory,19168263.0,
264,426893,7,6,,104234147,3779,Active,461604.0,155.0,0.1,EC50,Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay,Confirmatory,19581100.0,
265,426894,7,6,,104234147,3779,Active,461604.0,155.0,1.0,EC50,Agonist activity at human cloned adrenergic beta3 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,Confirmatory,19581100.0,
266,426895,7,6,,104234147,3779,Active,296439450.0,154.0,0.003,EC50,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay,Confirmatory,19581100.0,
267,426896,7,6,,104234147,3779,Active,296439450.0,154.0,1.0,EC50,Agonist activity at human cloned adrenergic beta2 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,Confirmatory,19581100.0,
268,426897,7,6,,104234147,3779,Active,48429211.0,153.0,0.012,EC50,Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay,Confirmatory,19581100.0,
269,426898,8,1,,104234147,3779,Active,48429211.0,153.0,1.0,EC50,Agonist activity at human cloned adrenergic beta-1 receptor expressed in CHO cells assessed as [125I]cAMP accumulation after 2 days by radioimmunoassay relative to isoproterenol,Confirmatory,19581100.0,
270,429597,5,6,,104234147,3779,Active,461604.0,155.0,0.002,EC50,Agonist activity at human recombinant adrenergic beta3 receptor expressed in CHO cells assessed as stimulation of cAMP level after 1 hr by enzyme immunoassay,Confirmatory,19608416.0,
271,429598,5,6,,104234147,3779,Active,296439450.0,154.0,0.00084,EC50,Agonist activity at human recombinant adrenergic beta2 receptor expressed in CHO cells assessed as stimulation of cAMP level after 1 hr by enzyme immunoassay,Confirmatory,19608416.0,
272,463106,1,2,,90340610,3779,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
273,483557,6,6,,104234147,3779,Active,296439450.0,154.0,0.039810000000000005,EC50,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,Confirmatory,20462258.0,
274,483558,3,10,,104234147,3779,Unspecified,296439450.0,154.0,,,Agonist activity at human recombinant beta2 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation at 10 mM after 30 to 45 mins relative to isoprenaline,Other,20462258.0,
275,483559,7,1,,104234147,3779,Active,48429211.0,153.0,0.007940000000000001,EC50,Agonist activity at human recombinant beta-1 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,Confirmatory,20462258.0,
276,483560,7,1,,104234147,3779,Active,461604.0,155.0,0.039810000000000005,EC50,Agonist activity at human recombinant beta3 adrenergic receptor expressed in CHO cells assessed as induction of intracellular cAMP accumulation after 30 to 45 mins,Confirmatory,20462258.0,
277,485290,1,1,,26752240,3779,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
278,485295,1,2,,90340610,3779,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
279,485297,1,1,,90340610,3779,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
280,485298,1,1,,90340610,3779,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
281,485313,1,2,,90340610,3779,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
282,485342,1,2,,90340610,3779,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
283,485345,1,2,,90340610,3779,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
284,485366,1,2,,90340610,3779,Inconclusive,4501969.0,154.0,1.2995,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
285,485368,1,2,,90340610,3779,Inconclusive,72386991.0,3656265.0,0.8492,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
286,488772,1,1,,90340610,3779,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
287,488773,1,2,,90340610,3779,Active,8659577.0,58819.0,9.4662,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
288,488816,1,1,,90340610,3779,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
289,488837,1,1,,90340610,3779,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
290,488949,1,2,,90340610,3779,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
291,488953,1,1,,90340610,3779,Active,187960037.0,10951.0,0.0106,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
292,488978,1,1,,90340610,3779,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
293,488981,1,1,,90340610,3779,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
294,488982,1,1,,90340610,3779,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
295,488983,1,1,,90340610,3779,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
296,493106,1,1,,90340610,3779,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
297,493107,1,1,,90340610,3779,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
298,493153,1,1,,90340610,3779,Inactive,,4780.0,20.5962,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
299,493153,1,1,,90340610,3779,Inactive,224028257.0,4780.0,20.5962,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
300,493164,1,2,,90340610,3779,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
301,493164,1,2,,90340610,3779,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
302,493164,1,2,,90340610,3779,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
303,496763,2,3,,104234147,3779,Active,,,,,Psychostimulant activity in zebrafish assessed as increase in high intensity light-induced motor response at 10 to 100 uM by photomotor response assay,Other,20081854.0,
304,496767,2,3,,104234147,3779,Inactive,,,,,Psychostimulant activity in zebrafish assessed as increase in high intensity light-induced motor response at < 10 uM by photomotor response assay,Other,20081854.0,
305,496768,3,4,,104234147,3779,Inactive,,,,,Anxiolytic activity in zebrafish assessed as decrease in high intensity light-induced motor behavior at <10 uM by photomotor response assay,Other,20081854.0,
306,496772,2,4,,104234147,3779,Active,,,,,Modulation of neurological behavior in zebrafish assessed as effect on touch response by high-throughput screening,Other,20081854.0,
307,503294,2,6,,104234147,3779,Active,,,,,Agonist activity at beta-2-adrenergic receptor expressed in HEK293 cells assessed as induction of receptor interaction with beta-arrestin by EYFP based reporter gene assay,Other,16680159.0,
308,503306,2,5,,104234147,3779,Unspecified,,,,,Antiproliferative activity against human PC3 cells at 2 uM after 120 hrs by MTT assay relative to DMSO,Other,16680159.0,
309,504327,1,1,,90340610,3779,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
310,504332,1,1,,90340610,3779,Active,168985070.0,,14.1254,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
311,504536,1,1,,90340610,3779,Inactive,5453898.0,5300.0,,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
312,504547,1,1,,90340610,3779,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
313,504548,1,2,,90340610,3779,Inconclusive,157877932.0,5655980.0,23.9341,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
314,504749,1,3,,26752240,3779,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
315,504749,1,3,,104171176,3779,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
316,504749,1,3,1.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
317,504749,1,3,2.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
318,504749,1,3,3.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
319,504749,1,3,4.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
320,504749,1,3,5.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
321,504749,1,3,6.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
322,504749,1,3,7.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
323,504749,1,3,8.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
324,504749,1,3,9.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
325,504749,1,3,10.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
326,504749,1,3,11.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
327,504749,1,3,12.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
328,504749,1,3,13.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
329,504749,1,3,14.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
330,504749,1,3,15.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
331,504749,1,3,16.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
332,504749,1,3,17.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
333,504749,1,3,18.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
334,504749,1,3,19.0,26752240,3779,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
335,504749,1,3,20.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
336,504749,1,3,21.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
337,504749,1,3,22.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
338,504749,1,3,23.0,104171176,3779,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
339,504749,1,3,24.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
340,504749,1,3,25.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
341,504749,1,3,26.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
342,504749,1,3,27.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
343,504749,1,3,28.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
344,504749,1,3,29.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
345,504749,1,3,30.0,104171176,3779,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
346,504749,1,3,31.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
347,504749,1,3,32.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
348,504749,1,3,33.0,104171176,3779,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
349,504749,1,3,34.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
350,504749,1,3,35.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
351,504749,1,3,36.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
352,504749,1,3,37.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
353,504749,1,3,38.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
354,504749,1,3,39.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
355,504749,1,3,40.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
356,504749,1,3,41.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
357,504749,1,3,42.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
358,504749,1,3,43.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
359,504749,1,3,44.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
360,504749,1,3,45.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
361,504749,1,3,46.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
362,504749,1,3,47.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
363,504749,1,3,48.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
364,504749,1,3,49.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
365,504749,1,3,50.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
366,504749,1,3,51.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
367,504749,1,3,52.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
368,504749,1,3,53.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
369,504749,1,3,54.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
370,504749,1,3,55.0,104171176,3779,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
371,504749,1,3,56.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
372,504749,1,3,57.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
373,504749,1,3,58.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
374,504749,1,3,59.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
375,504749,1,3,60.0,104171176,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
376,504749,1,3,61.0,26752240,3779,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
377,504810,1,2,,90340610,3779,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
378,504812,1,2,,90340610,3779,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
379,504832,1,1,,104171176,3779,Inconclusive,,,15.1014,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
380,504834,1,1,,104171176,3779,Inconclusive,,,4.2562,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
381,504836,1,2,,90340610,3779,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
382,504845,1,1,,90340610,3779,Inconclusive,86301163.0,5999.0,42.2841,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
383,504845,1,1,,104171176,3779,Inconclusive,86301163.0,5999.0,0.1683,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
384,504847,1,1,,90340610,3779,Active,63054845.0,7421.0,79.4328,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
385,504847,1,1,,104171176,3779,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
386,504865,1,1,,90340610,3779,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
387,504865,1,1,,104171176,3779,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
388,513146,4,2,,104234147,3779,Active,,,0.09,Ki,Binding affinity to human beta-2 adrenergic receptor delta 5-C271 mutant expressed in Spodoptera frugiperda Sf9 cells,Confirmatory,16799554.0,
389,513148,2,3,,104234147,3779,Unspecified,,,,,Agonist activity at human Beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as decrease in bimane fluorescence intensity by fluorescence spectroscopy,Other,16799554.0,
390,513149,4,2,,104234147,3779,Active,,,0.15,IC50,Displacement of [3H]dihydroalprenolol from human beta-2 adrenergic receptor delta 5-C271/W135 mutant labeled with bimane by competition binding assay,Confirmatory,16799554.0,
391,513150,4,2,,104234147,3779,Active,,,0.37,IC50,Displacement of [3H]dihydroalprenolol from human beta-2 adrenergic receptor delta 5-C271/W135 mutant by competition binding assay,Confirmatory,16799554.0,
392,513151,2,4,,104234147,3779,Active,,,,,Agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as stimulation of [35S]GTPgammaS binding [35S]GTPgammaS binding assay,Other,16799554.0,
393,513152,2,3,,104234147,3779,Unspecified,,,,,Partial agonist activity at human biamane labelled beta-2 adrenergic receptor delta 5-C271/Trp135 mutant assessed as bimane response by fluorescence spectroscopy,Other,16799554.0,
394,513154,4,2,,104234147,3779,Active,,,0.05,Ki,Binding affinity to human beta-2 adrenergic receptor delta 5-C271/W135 mutant expressed in Spodoptera frugiperda Sf9 cells,Confirmatory,16799554.0,
395,540209,4,3,,104234147,3779,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
396,540210,4,3,,104234147,3779,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
397,540211,2,5,,104234147,3779,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
398,540212,4,3,,104234147,3779,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
399,540213,4,3,,104234147,3779,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
400,540256,1,2,,90340610,3779,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
401,540276,1,2,,26752240,3779,Inconclusive,420597.0,,0.4108,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
402,540276,1,2,,50104946,3779,Inconclusive,420597.0,,0.4108,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
403,540276,1,2,,50111114,3779,Inconclusive,420597.0,,0.4108,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
404,540276,1,2,,90340610,3779,Inconclusive,420597.0,,0.4108,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
405,540276,1,2,,104171176,3779,Inconclusive,420597.0,,0.4108,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
406,580169,2,3,,104234147,3779,Unspecified,,,,,Induction of lipolysis in mouse C3H10T1/2 assessed as glycerol concentration at 10 uM relative to control,Other,21330134.0,
407,580170,2,3,,104234147,3779,Unspecified,,,,,Induction of lipolysis in human Adipocyte assessed as glycerol concentration at 10 uM relative to control,Other,21330134.0,
408,580171,2,3,,104234147,3779,Active,,,0.019,EC50,Induction of lipolysis in mouse C3H10T1/2 assessed as glycerol concentration,Confirmatory,21330134.0,
409,588211,2,3,,104234147,3779,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
410,588212,2,3,,104234147,3779,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
411,588213,2,3,,104234147,3779,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
412,588349,1,1,,90340610,3779,Inactive,,,,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
413,588378,1,1,,90340610,3779,Inactive,171543895.0,6311.0,,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
414,588453,1,1,,90340610,3779,Inconclusive,8659577.0,58819.0,14.1254,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
415,588456,1,1,,90340610,3779,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
416,588579,1,1,,90340610,3779,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
417,588579,1,1,,104171176,3779,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
418,588795,1,1,,90340610,3779,Inactive,4758356.0,2237.0,,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
419,588834,2,1,,26752240,3779,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
420,602332,1,1,,90340610,3779,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
421,602332,1,1,,104171176,3779,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
422,606103,4,6,,104234147,3779,Active,296439450.0,154.0,0.039810000000000005,EC50,Agonist activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr,Confirmatory,21652207.0,
423,606104,1,9,,104234147,3779,Unspecified,296439450.0,154.0,,,Intrinsic activity at human adrenergic beta2 receptor expressed in H292 cells assessed as intracellular cAMP accumulation after 1 hr relative to formoterol,Other,21652207.0,
424,611235,1,5,,104234147,3779,Inconclusive,,,,,Metabolic stability in human liver microsomes with 125 pmol/mL P450 assessed as compound turnover ratio at 5 uM after 30 mins by LC-MS method relative to verapamil,Other,21696967.0,
425,611236,4,6,,104234147,3779,Active,461604.0,155.0,0.039810000000000005,EC50,Agonist activity at human adrenergic beta3 receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,21696967.0,
426,611237,4,6,,104234147,3779,Active,48429211.0,153.0,0.007940000000000001,EC50,Agonist activity at human adrenergic beta1 receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,21696967.0,
427,611238,1,9,,104234147,3779,Unspecified,296439450.0,154.0,,,Intrinsic activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cyclic AMP accumulation relative to isoprenaline,Other,21696967.0,
428,611239,4,6,,104234147,3779,Active,296439450.0,154.0,0.039810000000000005,EC50,Agonist activity at human adrenergic beta2 receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,21696967.0,
429,623252,4,6,,104234147,3779,Active,296439450.0,154.0,0.039810000000000005,EC50,Agonist activity at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,21925889.0,
430,623253,1,9,,104234147,3779,Unspecified,296439450.0,154.0,,,Intrinsic activity at at human beta2 receptor expressed in CHO cells assessed as cAMP accumulation,Other,21925889.0,
431,623254,4,6,,104234147,3779,Active,48429211.0,153.0,0.007940000000000001,EC50,Agonist activity at human beta1 receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,21925889.0,
432,623255,4,6,,104234147,3779,Active,461604.0,155.0,0.039810000000000005,EC50,Agonist activity at human beta3 receptor expressed in CHO cells assessed as cAMP accumulation,Confirmatory,21925889.0,
433,623256,1,5,,104234147,3779,Inconclusive,,,,,Metabolic stability in human liver microsomes assessed as compound turn over ratio relative to verapamil,Other,21925889.0,
434,624030,1,2,,104171176,3779,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
435,624031,1,2,,104171176,3779,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
436,624032,1,2,,104171176,3779,Inconclusive,8393992.0,24660.0,0.9074,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
437,624044,1,2,,104171176,3779,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
438,624146,1,1,,90340610,3779,Inconclusive,71051501.0,2744.0,0.631,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
439,624147,1,1,,90340610,3779,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
440,624148,1,2,,90340610,3779,Inconclusive,1724069.0,2740.0,0.3663,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
441,624149,1,1,,90340610,3779,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
442,624170,1,1,,104171176,3779,Inactive,71051501.0,2744.0,11.2202,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
443,624172,1,1,,104171176,3779,Inconclusive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
444,624173,1,3,,104171176,3779,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
445,624296,1,1,,26752240,3779,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
446,624296,1,1,,104171176,3779,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
447,624297,1,1,,26752240,3779,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
448,624297,1,1,,104171176,3779,Inconclusive,7705682.0,51053.0,33.4983,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
449,624349,1,2,,92308688,3779,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
450,624455,1,1,,90340610,3779,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
451,625144,5,5,,104234147,3779,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
452,625145,4,7,,104234147,3779,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
453,625146,5,5,,104234147,3779,Active,126397.0,100009114.0,1.77,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
454,625147,4,7,,104234147,3779,Unspecified,395398606.0,4159.0,,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
455,625148,4,7,,104234147,3779,Unspecified,60392672.0,4160.0,,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
456,625149,4,7,,104234147,3779,Unspecified,729996.0,4161.0,,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
457,625150,5,5,,104234147,3779,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
458,625151,4,7,,104234147,3779,Unspecified,113118.0,1128.0,,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
459,625152,4,7,,104234147,3779,Unspecified,113122.0,1129.0,,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
460,625153,4,7,,104234147,3779,Unspecified,113125.0,1131.0,,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
461,625154,4,7,,104234147,3779,Unspecified,23503039.0,1132.0,,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
462,625155,4,7,,104234147,3779,Unspecified,543761.0,1133.0,,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
463,625156,1,9,,104234147,3779,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
464,625157,6,2,,104234147,3779,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
465,625158,3,4,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
466,625159,5,5,,104234147,3779,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
467,625160,1,9,,104234147,3779,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
468,625161,4,7,,104234147,3779,Unspecified,311033488.0,4985.0,,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
469,625162,4,7,,104234147,3779,Unspecified,116242691.0,4986.0,,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
470,625163,4,7,,104234147,3779,Unspecified,2851402.0,4988.0,,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
471,625164,1,6,,104234147,3779,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
472,625165,3,4,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
473,625166,3,4,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
474,625167,5,5,,104234147,3779,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
475,625168,4,7,,104234147,3779,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
476,625169,1,6,,104234147,3779,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
477,625170,3,4,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
478,625171,4,7,,104234147,3779,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
479,625172,4,7,,104234147,3779,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
480,625173,5,5,,104234147,3779,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
481,625174,5,5,,104234147,3779,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
482,625175,5,5,,104234147,3779,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
483,625176,1,9,,104234147,3779,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
484,625177,5,5,,104234147,3779,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
485,625178,5,5,,104234147,3779,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
486,625179,1,9,,104234147,3779,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
487,625180,5,5,,104234147,3779,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
488,625181,5,5,,104234147,3779,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
489,625182,5,5,,104234147,3779,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
490,625183,5,5,,104234147,3779,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
491,625184,5,5,,104234147,3779,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
492,625185,5,5,,104234147,3779,Unspecified,125370.0,2534.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
493,625186,5,5,,104234147,3779,Unspecified,119533.0,2064.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
494,625187,5,5,,104234147,3779,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
495,625188,1,9,,104234147,3779,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
496,625189,1,7,,104234147,3779,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
497,625190,4,5,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
498,625191,4,7,,104234147,3779,Unspecified,112815.0,25075.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
499,625192,4,7,,104234147,3779,Unspecified,543727.0,3356.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
500,625193,5,5,,104234147,3779,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
501,625194,4,7,,104234147,3779,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
502,625195,4,7,,104234147,3779,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
503,625196,5,6,,104234147,3779,Unspecified,803374855.0,140.0,,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
504,625197,3,4,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
505,625198,4,7,,104234147,3779,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
506,625199,4,7,,104234147,3779,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
507,625200,4,7,,104234147,3779,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
508,625201,4,7,,104234147,3779,Unspecified,1351829.0,150.0,,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
509,625202,4,7,,104234147,3779,Unspecified,613504690.0,151.0,,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
510,625203,4,7,,104234147,3779,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
511,625204,4,7,,104234147,3779,Active,48429211.0,153.0,0.33299999999999996,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
512,625205,4,7,,104234147,3779,Active,296439450.0,154.0,0.24600000000000002,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
513,625206,4,7,,104234147,3779,Unspecified,461604.0,155.0,,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
514,625207,4,7,,104234147,3779,Unspecified,128616.0,6530.0,,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
515,625208,5,5,,104234147,3779,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
516,625209,4,7,,104234147,3779,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
517,625210,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
518,625211,1,6,,104234147,3779,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
519,625212,3,4,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
520,625213,4,7,,104234147,3779,Unspecified,2506481.0,624.0,,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
521,625214,1,9,,104234147,3779,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
522,625215,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
523,625216,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
524,625217,4,7,,104234147,3779,Unspecified,1168220.0,3357.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
525,625218,4,7,,104234147,3779,Unspecified,112816.0,3358.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
526,625219,3,4,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
527,625220,4,7,,104234147,3779,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
528,625221,4,7,,104234147,3779,Unspecified,1703010.0,3362.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
529,625222,4,7,,104234147,3779,Unspecified,400630.0,6532.0,,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
530,625223,4,7,,104234147,3779,Unspecified,74752153.0,10280.0,,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
531,625224,3,4,,104234147,3779,Unspecified,,,,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
532,625225,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
533,625226,4,7,,104234147,3779,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
534,625227,4,7,,104234147,3779,Unspecified,229462950.0,6865.0,,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
535,625228,4,7,,104234147,3779,Unspecified,113832.0,24208.0,,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
536,625229,5,5,,104234147,3779,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
537,625230,1,6,,104234147,3779,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
538,625231,4,7,,104234147,3779,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
539,625232,1,9,,104234147,3779,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
540,625233,4,7,,104234147,3779,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
541,625234,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
542,625235,4,7,,104234147,3779,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
543,625236,5,5,,104234147,3779,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
544,625237,4,7,,104234147,3779,Unspecified,1168965.0,729230.0,,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
545,625238,4,7,,104234147,3779,Unspecified,1705894.0,1233.0,,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
546,625239,4,7,,104234147,3779,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
547,625240,1,9,,104234147,3779,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
548,625241,4,7,,104234147,3779,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
549,625242,4,7,,104234147,3779,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
550,625243,5,5,,104234147,3779,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
551,625244,5,5,,104234147,3779,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
552,625245,5,5,,104234147,3779,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
553,625246,1,9,,104234147,3779,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
554,625247,5,5,,104234147,3779,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
555,625248,5,5,,104234147,3779,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
556,625249,5,5,,104234147,3779,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
557,625250,5,5,,104234147,3779,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
558,625251,5,5,,104234147,3779,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
559,625252,4,7,,104234147,3779,Unspecified,118228.0,1812.0,,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
560,625253,4,7,,104234147,3779,Unspecified,118206.0,1813.0,,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
561,625254,4,7,,104234147,3779,Unspecified,1169206.0,1814.0,,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
562,625255,4,7,,104234147,3779,Unspecified,1345939.0,1815.0,,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
563,625256,4,7,,104234147,3779,Unspecified,266667.0,6531.0,,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
564,625257,4,7,,104234147,3779,Unspecified,119606.0,1909.0,,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
565,625258,4,7,,104234147,3779,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
566,625259,4,7,,104234147,3779,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
567,625260,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
568,625261,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
569,625262,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
570,625263,4,7,,104234147,3779,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
571,625264,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
572,625265,1,6,,104234147,3779,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
573,625266,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
574,625267,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
575,625268,4,2,,104234147,3779,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
576,625268,4,2,,104234147,3779,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
577,625268,4,2,,104234147,3779,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
578,625268,4,2,,104234147,3779,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
579,625269,4,7,,104234147,3779,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
580,625270,4,7,,104234147,3779,Unspecified,123120.0,3274.0,,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
581,625271,5,5,,104234147,3779,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
582,625272,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
583,625273,4,6,,104234147,3779,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
584,625274,1,6,,104234147,3779,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
585,625275,3,4,,104234147,3779,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
586,625278,1,3,,104234147,3779,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of no concern for DILI,Other,21624500.0,
587,625279,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
588,625280,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
589,625281,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
590,625282,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
591,625283,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
592,625284,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
593,625285,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
594,625286,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
595,625287,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
596,625288,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
597,625289,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
598,625290,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
599,625291,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
600,625292,1,3,,104234147,3779,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
601,647421,4,6,,104234147,3779,Unspecified,81914759.0,100722663.0,,EC50,Agonist activity at beta2 adrenoceptor in guinea pig assessed as relaxation of histamine-induced tracheal ring contraction,Confirmatory,22297114.0,
602,651631,4,1,,144203723,3779,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
603,651632,4,1,,144203723,3779,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
604,651633,4,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
605,651634,4,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
606,651635,1,3,,90340610,3779,Inconclusive,171543895.0,6311.0,19.9526,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
607,651741,1,1,,124880429,3779,Inconclusive,20149576.0,4780.0,,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
608,651828,1,2,,92308688,3779,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
609,652048,1,2,,144203723,3779,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
610,652051,1,1,,144203723,3779,Active,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
611,652106,1,1,,90340610,3779,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
612,686978,1,1,,144203723,3779,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
613,686979,1,1,,144203723,3779,Inconclusive,79154014.0,55775.0,26.6086,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
614,708935,1,3,,104234147,3779,Unspecified,,,,,Effect on heart rate in C57BL/6 mouse Langendorff perfused heart at 100 uM measured for 20 mins,Other,23072318.0,
615,708936,1,2,,104234147,3779,Unspecified,,,,,Positive inotropic activity in C57BL/6 mouse Langendorff perfused heart assessed as rate of relaxation at 100 uM measured for 20 mins,Other,23072318.0,
616,708937,1,2,,104234147,3779,Unspecified,,,,,Positive inotropic activity in C57BL/6 mouse Langendorff perfused heart assessed as rate of contraction at 100 uM measured for 20 mins,Other,23072318.0,
617,708938,1,2,,104234147,3779,Unspecified,,,,,Positive inotropic activity in C57BL/6 mouse Langendorff perfused heart assessed as left ventricular developed pressure at 100 uM measured for 20 mins,Other,23072318.0,
618,720516,2,1,,144203723,3779,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
619,720532,1,1,,144203723,3779,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
620,720533,1,1,,144203723,3779,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
621,720538,1,2,,90340610,3779,Inconclusive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
622,720552,2,1,,144203723,3779,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
623,720559,1,2,,90340610,3779,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
624,720572,1,2,,90340610,3779,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
625,720573,1,2,,90340610,3779,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
626,720634,2,1,,144203723,3779,Inactive,,,6.6824,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
627,720635,2,1,,144203723,3779,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
628,720636,1,1,,124880429,3779,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
629,720637,2,1,,144203723,3779,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
630,720641,1,2,,92308688,3779,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
631,720674,2,2,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
632,720675,2,2,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
633,720678,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
634,720679,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
635,720680,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
636,720681,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
637,720682,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
638,720683,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
639,720684,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
640,720685,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
641,720686,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
642,720687,2,2,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
643,720691,4,1,,144203723,3779,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
644,720692,3,1,,144203723,3779,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
645,720693,3,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
646,720717,1,3,,92308688,3779,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
647,720719,2,1,,144203723,3779,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
648,720725,2,1,,144203723,3779,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
649,735055,2,5,,104234147,3779,Unspecified,81914759.0,100722663.0,,EC50,Agonist activity at beta2-adrenoceptor in guinea pig trachea assessed as relaxation of histamine-induced precontracted tracheal rings,Confirmatory,23375225.0,
650,743012,3,1,,144203723,3779,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
651,743014,3,1,,144203723,3779,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
652,743015,3,1,,144203723,3779,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
653,743033,3,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
654,743035,2,1,,144203723,3779,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
655,743036,2,1,,144203723,3779,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
656,743040,3,1,,144203723,3779,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
657,743041,3,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
658,743042,3,1,,144203723,3779,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
659,743053,2,1,,144203723,3779,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
660,743054,2,1,,144203723,3779,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
661,743063,2,1,,144203723,3779,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
662,743064,3,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
663,743065,3,1,,144203723,3779,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
664,743066,3,1,,144203723,3779,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
665,743067,2,1,,144203723,3779,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
666,743069,2,1,,144203723,3779,Inconclusive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
667,743074,2,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
668,743075,2,1,,144203723,3779,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
669,743077,2,1,,144203723,3779,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
670,743078,2,1,,144203723,3779,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
671,743079,3,1,,144203723,3779,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
672,743080,3,1,,144203723,3779,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
673,743081,3,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
674,743083,3,1,,144203723,3779,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
675,743084,3,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
676,743085,3,1,,144203723,3779,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
677,743086,3,1,,144203723,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
678,743091,2,1,,144203723,3779,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
679,743094,3,1,,144203723,3779,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
680,743122,2,1,,144203723,3779,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
681,743139,2,1,,144203723,3779,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
682,743140,2,1,,144203723,3779,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
683,743191,3,1,,170464679,3779,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
684,743194,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
685,743199,2,1,,170464679,3779,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
686,743202,4,1,,170464679,3779,Inconclusive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
687,743203,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
688,743205,1,1,,90340610,3779,Inactive,4503951.0,2645.0,28.1838,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
689,743205,1,1,,90340610,3779,Inactive,221625433.0,2646.0,28.1838,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
690,743206,1,1,,90340610,3779,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
691,743206,1,1,,90340610,3779,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
692,743207,1,1,,90340610,3779,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
693,743207,1,1,,90340610,3779,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
694,743209,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
695,743210,4,1,,170464679,3779,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
696,743211,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
697,743212,3,1,,170464679,3779,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
698,743213,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
699,743215,3,1,,170464679,3779,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
700,743217,3,1,,170464679,3779,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
701,743218,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
702,743219,3,1,,170464679,3779,Inconclusive,20149576.0,4780.0,10.5901,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
703,743220,3,1,,170464679,3779,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
704,743221,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
705,743222,3,1,,170464679,3779,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
706,743223,3,1,,170464679,3779,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
707,743224,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
708,743225,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
709,743226,2,1,,170464679,3779,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
710,743227,2,1,,170464679,3779,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
711,743228,3,1,,170464679,3779,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
712,743239,2,1,,170464679,3779,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
713,743240,2,1,,170464679,3779,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
714,743241,2,1,,170464679,3779,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
715,743242,2,1,,170464679,3779,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
716,743244,1,1,,90340610,3779,Inconclusive,,,3.1623,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
717,743244,1,1,,144203723,3779,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
718,743344,1,1,,104171176,3779,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
719,743345,1,1,,104171176,3779,Inactive,,,5.9518,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
720,743346,1,1,,104171176,3779,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
721,743347,1,1,,104171176,3779,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
722,770362,2,3,,104234147,3779,Active,296439450.0,154.0,0.25119,Kd,Binding affinity to beta-2 adrenergic receptor (unknown origin) at 1 to 10000 nM,Confirmatory,23954364.0,
723,770364,1,1,,104234147,3779,Inactive,,,,,Induction of Mitochondrial biogenesis in rabbit RPT cells at 10 to 3000 nM after 24 hrs by FCCP-OCR assay relative to control,Other,23954364.0,
724,781325,1,2,,104234147,3779,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Liao ref: J Chem Info Model 2009,Other,24249037.0,
725,927042,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070319,Other,,
726,927043,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070319,Other,,
727,927044,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070319,Other,,
728,927045,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070319,Other,,
729,927046,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070319,Other,,
730,927047,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070319,Other,,
731,927048,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070319,Other,,
732,927049,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070319,Other,,
733,927050,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070319,Other,,
734,927051,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070319,Other,,
735,927052,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070319,Other,,
736,927053,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070319,Other,,
737,927054,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070319,Other,,
738,927055,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070319,Other,,
739,927056,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070319,Other,,
740,927057,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070319,Other,,
741,927058,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070319,Other,,
742,930482,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070319,Other,,
743,930483,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070319,Other,,
744,930484,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070319,Other,,
745,930485,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070319,Other,,
746,930486,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070319,Other,,
747,930487,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070319,Other,,
748,930488,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070319,Other,,
749,930489,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070319,Other,,
750,930490,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070319,Other,,
751,930491,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070319,Other,,
752,930492,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070319,Other,,
753,930493,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070319,Other,,
754,930494,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070319,Other,,
755,930495,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070319,Other,,
756,930496,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070319,Other,,
757,930497,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070319,Other,,
758,930498,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070319,Other,,
759,930617,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S040818,Other,,
760,930618,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S040818,Other,,
761,930619,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S040818,Other,,
762,930620,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S040818,Other,,
763,930621,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S040818,Other,,
764,930622,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S040818,Other,,
765,930623,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S040818,Other,,
766,930901,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070319,Other,,
767,930902,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070319,Other,,
768,932639,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S040818,Other,,
769,932640,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S040818",Other,,
770,932641,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S040818,Other,,
771,932642,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S040818,Other,,
772,932643,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S040818,Other,,
773,932644,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S040818,Other,,
774,932919,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070319,Other,,
775,932920,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070319,Other,,
776,932921,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070319,Other,,
777,932922,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070319,Other,,
778,932923,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070319,Other,,
779,932924,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070319,Other,,
780,932925,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070319,Other,,
781,932926,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070319,Other,,
782,932927,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070319,Other,,
783,932928,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070319,Other,,
784,932929,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070319,Other,,
785,932930,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070319,Other,,
786,932931,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070319,Other,,
787,932932,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070319,Other,,
788,932933,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070319,Other,,
789,932934,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S040818,Other,,
790,932935,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S040818,Other,,
791,932936,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S040818,Other,,
792,932937,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S040818,Other,,
793,933273,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S040818,Other,,
794,933274,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S040818,Other,,
795,933275,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S040818,Other,,
796,933276,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S040818,Other,,
797,933277,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S040818,Other,,
798,933278,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S040818,Other,,
799,933566,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S040818,Other,,
800,933567,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S040818",Other,,
801,933568,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S040818,Other,,
802,933569,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S040818,Other,,
803,933570,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S040818,Other,,
804,933571,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S040818,Other,,
805,933572,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S040818,Other,,
806,933573,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S040818,Other,,
807,933574,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S040818,Other,,
808,933575,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S040818,Other,,
809,933576,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S040818,Other,,
810,933577,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S040818,Other,,
811,933578,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S040818,Other,,
812,933579,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S040818,Other,,
813,933580,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S040818,Other,,
814,936105,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S040818,Other,,
815,936106,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S040818,Other,,
816,936107,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S040818,Other,,
817,936108,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S040818",Other,,
818,936109,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S040818,Other,,
819,936110,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020819,Other,,
820,936111,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020819,Other,,
821,936112,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020819,Other,,
822,936113,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020819,Other,,
823,936114,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020819,Other,,
824,936115,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020819,Other,,
825,936116,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020819,Other,,
826,936117,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020819,Other,,
827,936118,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020819",Other,,
828,936119,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020819,Other,,
829,936120,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020819,Other,,
830,936748,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020819,Other,,
831,936749,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020819,Other,,
832,936750,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020819,Other,,
833,936751,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020819,Other,,
834,936752,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020819,Other,,
835,936753,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020819,Other,,
836,936754,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020819,Other,,
837,936755,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020819,Other,,
838,936756,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S020819,Other,,
839,936757,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S020819,Other,,
840,936758,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S020819,Other,,
841,936759,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S020819,Other,,
842,936760,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S020819,Other,,
843,936761,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S020819,Other,,
844,936762,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: S020819,Other,,
845,936763,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S020819,Other,,
846,936764,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S020819,Other,,
847,936765,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S020819,Other,,
848,936766,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: S020819,Other,,
849,936767,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: S020819,Other,,
850,936768,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S020819,Other,,
851,936769,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: NEUTSG (Neutrophils, Segmented); Study_ID: S020819",Other,,
852,936770,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: S020819,Other,,
853,936771,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S020819,Other,,
854,936772,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S020819,Other,,
855,936773,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S020819,Other,,
856,936774,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S020819,Other,,
857,944767,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: S040818,Other,,
858,944768,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: S040818,Other,,
859,944769,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: S040818,Other,,
860,944770,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: S040818,Other,,
861,944771,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: S040818,Other,,
862,944772,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: S040818,Other,,
863,944773,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: S040818,Other,,
864,944774,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: RBCNUC (Nucleated Erythrocytes); Study_ID: S040818,Other,,
865,944775,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: S040818,Other,,
866,944776,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: S040818,Other,,
867,944777,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: S040818,Other,,
868,944778,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: S040818,Other,,
869,944779,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: S040818,Other,,
870,944780,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: S040818,Other,,
871,955026,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S040818,Other,,
872,955027,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S040818,Other,,
873,955616,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S040818,Other,,
874,955617,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S040818,Other,,
875,955618,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S040818,Other,,
876,955619,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S040818,Other,,
877,955620,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S040818,Other,,
878,955621,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S040818,Other,,
879,955622,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S040818,Other,,
880,955623,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S040818,Other,,
881,955624,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S040818,Other,,
882,955625,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S040818,Other,,
883,955626,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S040818,Other,,
884,955627,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S040818,Other,,
885,955628,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S040818,Other,,
886,955629,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S040818,Other,,
887,955630,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S040818,Other,,
888,955631,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S040818,Other,,
889,955632,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020819,Other,,
890,955633,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020819,Other,,
891,955634,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020819,Other,,
892,955635,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020819,Other,,
893,955636,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020819,Other,,
894,955637,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020819,Other,,
895,955638,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020819,Other,,
896,955639,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020819,Other,,
897,955640,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020819,Other,,
898,955641,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020819,Other,,
899,957497,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020819,Other,,
900,957498,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020819,Other,,
901,957499,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020819,Other,,
902,957500,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020819,Other,,
903,957501,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020819,Other,,
904,957502,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020819,Other,,
905,957503,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020819,Other,,
906,957504,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020819,Other,,
907,957505,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020819,Other,,
908,957506,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S020819,Other,,
909,958095,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S020819,Other,,
910,958096,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S020819,Other,,
911,958097,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S020819,Other,,
912,958098,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S020819,Other,,
913,958099,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: S020819,Other,,
914,958100,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S020819,Other,,
915,958101,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S020819,Other,,
916,958102,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S020819,Other,,
917,958103,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S020819,Other,,
918,958104,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S020819,Other,,
919,958105,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S020819,Other,,
920,958106,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S020819,Other,,
921,958107,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S020819,Other,,
922,958108,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S020819,Other,,
923,958109,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S020819,Other,,
924,958110,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S020819,Other,,
925,958111,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S020819,Other,,
926,958112,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S020819,Other,,
927,961547,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070319,Other,,
928,961548,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070319,Other,,
929,961549,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070319,Other,,
930,961550,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070319,Other,,
931,961551,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070319,Other,,
932,961552,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070319,Other,,
933,961553,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070319,Other,,
934,961554,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070319,Other,,
935,961555,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070319,Other,,
936,961556,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070319,Other,,
937,961557,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070319,Other,,
938,961558,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070319,Other,,
939,961559,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070319,Other,,
940,961560,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070319,Other,,
941,961561,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070319,Other,,
942,961562,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070319,Other,,
943,961563,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070319,Other,,
944,961564,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070319,Other,,
945,964114,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070319,Other,,
946,964115,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070319,Other,,
947,964116,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R070319,Other,,
948,964117,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070319,Other,,
949,964118,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070319,Other,,
950,964119,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070319,Other,,
951,964120,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070319,Other,,
952,964121,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070319,Other,,
953,964122,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070319,Other,,
954,964123,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070319,Other,,
955,964124,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070319,Other,,
956,964125,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070319,Other,,
957,964126,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070319,Other,,
958,964127,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070319,Other,,
959,964128,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070319,Other,,
960,964129,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070319,Other,,
961,964130,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070319,Other,,
962,964131,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070319,Other,,
963,964132,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070319,Other,,
964,969631,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S040818,Other,,
965,969632,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S040818,Other,,
966,969633,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S040818,Other,,
967,969634,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S040818,Other,,
968,969635,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S040818,Other,,
969,969636,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S040818,Other,,
970,969637,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S040818,Other,,
971,969638,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S040818,Other,,
972,969639,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S040818,Other,,
973,969640,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S040818,Other,,
974,969641,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S040818,Other,,
975,971663,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S040818,Other,,
976,971664,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S040818,Other,,
977,971665,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S040818,Other,,
978,971666,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S040818,Other,,
979,971667,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S040818,Other,,
980,971668,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S040818,Other,,
981,971669,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S040818,Other,,
982,973980,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070319,Other,,
983,973981,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070319,Other,,
984,973982,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070319,Other,,
985,973983,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070319,Other,,
986,973984,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070319,Other,,
987,973985,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070319,Other,,
988,973986,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070319,Other,,
989,974618,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070319,Other,,
990,974619,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070319,Other,,
991,974620,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070319,Other,,
992,974621,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070319,Other,,
993,974622,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070319,Other,,
994,974623,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070319,Other,,
995,974624,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070319,Other,,
996,974625,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070319,Other,,
997,974626,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070319,Other,,
998,974627,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070319,Other,,
999,974628,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070319,Other,,
1000,974629,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: S040818,Other,,
1001,974630,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: S040818,Other,,
1002,974631,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: S040818,Other,,
1003,974632,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: S040818,Other,,
1004,974633,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: S040818,Other,,
1005,974634,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: S040818,Other,,
1006,976658,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: S040818,Other,,
1007,976659,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: S040818,Other,,
1008,976660,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: S040818,Other,,
1009,976661,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: S040818,Other,,
1010,976662,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: S040818,Other,,
1011,976663,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: S040818,Other,,
1012,976664,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: S040818,Other,,
1013,976665,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: S040818,Other,,
1014,976666,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: S040818,Other,,
1015,976667,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: S040818,Other,,
1016,976668,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: S040818,Other,,
1017,976669,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: S040818,Other,,
1018,999456,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020819",Other,,
1019,999457,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Hypertrophy; Study_ID: S020819",Other,,
1020,999458,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Erythrophagocytosis; Study_ID: S020819",Other,,
1021,999459,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Glycogen Accumulation; Study_ID: S020819",Other,,
1022,1000041,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1023,1001903,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Dilatation; Study_ID: S020819,Other,,
1024,1001904,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Mesothelial Cell, Hyperplasia; Study_ID: S020819",Other,,
1025,1001905,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular Fibrosis; Study_ID: S020819,Other,,
1026,1001906,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Atrophy; Study_ID: S020819",Other,,
1027,1001907,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Cytoplasm, Eosinophilia; Study_ID: S020819",Other,,
1028,1001908,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Degeneration; Study_ID: S020819",Other,,
1029,1001909,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Mineralization; Study_ID: S020819",Other,,
1030,1001910,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1031,1001911,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Apoptotic; Study_ID: S020819",Other,,
1032,1001912,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Subcapsular, Mineralization; Study_ID: S020819",Other,,
1033,1001913,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Extramedullary Hematopoiesis; Study_ID: S020819",Other,,
1034,1001914,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020819",Other,,
1035,1001915,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1036,1001916,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Apoptotic; Study_ID: S020819",Other,,
1037,1001917,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Diffuse, Cytoplasm, Eosinophilia; Study_ID: S020819",Other,,
1038,1001918,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020819",Other,,
1039,1001919,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Lipid Accumulation, Microvesicular; Study_ID: S020819",Other,,
1040,1001920,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Apoptotic; Study_ID: S020819",Other,,
1041,1001921,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Increased Mitoses; Study_ID: S020819",Other,,
1042,1001922,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Microvesicular; Study_ID: S020819",Other,,
1043,1001923,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Necrosis, Apoptotic; Study_ID: S020819",Other,,
1044,1001924,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Hypertrophy; Study_ID: S020819",Other,,
1045,1001925,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Macrovesicular; Study_ID: S020819",Other,,
1046,1001926,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: S020819,Other,,
1047,1001927,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Hyperplasia; Study_ID: S020819,Other,,
1048,1001928,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Hypertrophy; Study_ID: S020819",Other,,
1049,1001929,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Lipid Accumulation, Macrovesicular; Study_ID: S020819",Other,,
1050,1001930,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1051,1001931,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Fibrosis; Study_ID: S020819",Other,,
1052,1001932,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: S020819,Other,,
1053,1001933,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1054,1001934,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Microvesicular; Study_ID: S020819",Other,,
1055,1002516,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1056,1002517,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Nonzonal, Multinucleated; Study_ID: S020819",Other,,
1057,1002518,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Malignant Lymphoma; Study_ID: S020819,Other,,
1058,1002519,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Mixed Cell; Study_ID: S020819",Other,,
1059,1002520,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Inflammatory Cell Infiltrate, Neutrophilic; Study_ID: S020819",Other,,
1060,1002521,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Degeneration; Study_ID: S020819",Other,,
1061,1002522,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Lipid Accumulation, Microvesicular; Study_ID: S020819",Other,,
1062,1002523,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Lymphoid; Study_ID: S020819",Other,,
1063,1004394,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Oval Cell, Hyperplasia; Study_ID: S020819",Other,,
1064,1004395,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Subcapsular, Fibrosis; Study_ID: S020819",Other,,
1065,1004396,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Capsule, Thrombus; Study_ID: S020819",Other,,
1066,1004397,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Clear Cell Focus; Study_ID: S020819,Other,,
1067,1004398,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Cytoplasm, Eosinophilia; Study_ID: S020819",Other,,
1068,1004399,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Glycogen Accumulation; Study_ID: S020819",Other,,
1069,1004400,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Nonzonal, Inflammatory Cell Infiltrate, Granulomatous; Study_ID: S020819",Other,,
1070,1004401,1,3,,104234147,3779,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Autolysis; Study_ID: S020819,Other,,
1071,1004402,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1072,1004403,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Glycogen Accumulation; Study_ID: S020819",Other,,
1073,1004404,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Centrilobular, Lipid Accumulation, Macrovesicular; Study_ID: S020819",Other,,
1074,1004405,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Midzonal, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1075,1004406,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Periportal, Necrosis, Oncocytic; Study_ID: S020819",Other,,
1076,1004407,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % saline; Route: intravenous | Dataset: Pathology; Tissue: Liver; Assay: Periportal, Edema; Study_ID: S020819",Other,,
1077,1005356,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S040818",Other,,
1078,1005357,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S040818",Other,,
1079,1005358,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1080,1005359,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1081,1005360,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S040818",Other,,
1082,1005361,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1083,1005362,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S040818",Other,,
1084,1005363,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S040818",Other,,
1085,1005364,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1086,1005365,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1087,1005366,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S040818",Other,,
1088,1005367,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1089,1005368,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S040818",Other,,
1090,1005369,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1091,1005370,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1092,1005371,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S040818",Other,,
1093,1005372,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S040818",Other,,
1094,1005373,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1095,1005374,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1096,1005375,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S040818",Other,,
1097,1005376,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S040818",Other,,
1098,1012761,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1099,1012762,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070319",Other,,
1100,1012763,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
1101,1012764,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070319",Other,,
1102,1012765,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070319",Other,,
1103,1012766,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070319",Other,,
1104,1012767,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070319",Other,,
1105,1012768,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070319",Other,,
1106,1012769,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070319",Other,,
1107,1012770,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070319",Other,,
1108,1012771,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1109,1012772,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
1110,1012773,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070319",Other,,
1111,1012774,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1112,1012775,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070319",Other,,
1113,1012776,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1114,1012777,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070319",Other,,
1115,1012778,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070319",Other,,
1116,1012779,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070319",Other,,
1117,1012780,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070319",Other,,
1118,1012781,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070319",Other,,
1119,1012782,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1120,1012783,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1121,1012784,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S040818",Other,,
1122,1012785,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S040818",Other,,
1123,1012786,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1124,1012787,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S040818",Other,,
1125,1012788,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1126,1012789,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1127,1012790,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S040818",Other,,
1128,1012791,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S040818",Other,,
1129,1015850,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1130,1015851,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1131,1015852,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1132,1015853,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: S040818",Other,,
1133,1015854,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1134,1015855,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1135,1015856,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: S040818",Other,,
1136,1015857,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: S040818",Other,,
1137,1015858,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: S040818",Other,,
1138,1015859,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: S040818",Other,,
1139,1015860,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: S040818",Other,,
1140,1015861,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1141,1015862,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: S040818",Other,,
1142,1016448,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: S040818",Other,,
1143,1016449,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1144,1016450,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1145,1016451,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1146,1024496,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1147,1024497,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1148,1024498,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: S040818",Other,,
1149,1024499,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: S040818",Other,,
1150,1024500,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1151,1024501,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: S040818",Other,,
1152,1024502,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: S040818",Other,,
1153,1024503,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: S040818",Other,,
1154,1024504,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1155,1024505,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: S040818",Other,,
1156,1024506,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: S040818",Other,,
1157,1024507,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: S040818",Other,,
1158,1024508,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: S040818",Other,,
1159,1024509,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: M1; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: S040818",Other,,
1160,1027858,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070319",Other,,
1161,1027859,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1162,1027860,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
1163,1027861,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070319",Other,,
1164,1027862,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070319",Other,,
1165,1027863,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070319",Other,,
1166,1027864,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070319",Other,,
1167,1027865,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070319",Other,,
1168,1027866,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070319",Other,,
1169,1027867,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070319",Other,,
1170,1027868,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1171,1027869,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070319",Other,,
1172,1027870,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070319",Other,,
1173,1027871,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
1174,1027872,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070319",Other,,
1175,1027873,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070319",Other,,
1176,1027874,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070319",Other,,
1177,1027875,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070319",Other,,
1178,1027876,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1179,1027877,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070319",Other,,
1180,1027878,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1181,1033114,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1182,1033115,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
1183,1033116,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070319",Other,,
1184,1033117,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070319",Other,,
1185,1033118,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070319",Other,,
1186,1033119,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070319",Other,,
1187,1033120,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070319",Other,,
1188,1033121,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070319",Other,,
1189,1033122,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070319",Other,,
1190,1033123,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1191,1034989,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070319",Other,,
1192,1034990,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070319",Other,,
1193,1034991,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
1194,1034992,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070319",Other,,
1195,1034993,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070319",Other,,
1196,1034994,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1197,1034995,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070319",Other,,
1198,1034996,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070319",Other,,
1199,1034997,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070319",Other,,
1200,1034998,1,4,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070319",Other,,
1201,1034999,1,3,,104234147,3779,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: Low; Vehicle: 100 % saline; Route: mini-pump - subcutaneous | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
1202,1060999,4,2,,104234147,3779,Unspecified,81914759.0,100722663.0,,EC50,Agonist activity at guinea pig trachea beta2-adrenergic receptor assessed as relaxation of histamine-induced tracheal ring contraction,Confirmatory,24300734.0,
1203,1061253,1,4,,104234147,3779,Unspecified,296439450.0,154.0,,,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as stimulation of cAMP accumulation relative to isoproterenol,Other,24326276.0,
1204,1061254,3,1,,104234147,3779,Active,296439450.0,154.0,0.0002,EC50,Agonist activity at human beta2 adrenergic receptor expressed in HEK293 cells assessed as stimulation of cAMP accumulation,Confirmatory,24326276.0,
1205,1061255,4,2,,104234147,3779,Active,296439450.0,154.0,0.00244,Ki,"Displacement of [3H]-(R,R')-methoxyfenoterol from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis",Confirmatory,24326276.0,
1206,1061256,2,3,,104234147,3779,Active,296439450.0,154.0,0.192,Ki,Displacement of [3H]-CGP-12177 from human beta2 adrenergic receptor expressed in HEK cells by liquid scintillation counting analysis,Confirmatory,24326276.0,
1207,1117298,1,2,,170464679,3779,Inactive,,,0.631,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1208,1117301,1,2,,170464679,3779,Inactive,,,2.2387,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
1209,1117302,1,2,,170464679,3779,Inactive,,,1.7783,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
1210,1117303,1,2,,170464679,3779,Inactive,,,1.78,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
1211,1117304,1,2,,170464679,3779,Inactive,,,4.4668,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1212,1117305,1,2,,170464679,3779,Inactive,,,1.4125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1213,1117310,1,1,,170464679,3779,Inactive,,,0.630957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1214,1117311,1,1,,170464679,3779,Inactive,,,2.2387200000000003,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
1215,1117312,1,1,,170464679,3779,Inactive,,,1.41254,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1216,1117314,1,1,,170464679,3779,Inactive,,,4.46684,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1217,1117315,1,1,,170464679,3779,Inactive,,,1.7782799999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
1218,1117318,1,1,,170464679,3779,Inactive,,,1.7782799999999999,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
1219,1117326,1,1,,170464679,3779,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1220,1117329,1,1,,170464679,3779,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
1221,1117336,1,1,,170464679,3779,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1222,1117340,1,1,,170464679,3779,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
1223,1117341,1,1,,170464679,3779,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
1224,1117342,1,1,,170464679,3779,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1225,1117343,1,1,,170464679,3779,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1226,1117346,1,1,,170464679,3779,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1227,1123872,1,1,,104234147,3779,Unspecified,,,,,"Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of anoxia at 1.25 mg/kg, po treated 30 mins before histamine challenge (Rvb = 5.08 mins)",Other,423210.0,
1228,1123873,1,1,,104234147,3779,Unspecified,,,,,"Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of anoxia at 5 mg/kg, po treated 30 mins before histamine challenge (Rvb = 5.08 mins)",Other,423210.0,
1229,1123874,1,1,,104234147,3779,Unspecified,,,,,"Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of coughing at 1.25 mg/kg, po treated 30 mins before histamine challenge (Rvb = 6.13 mins)",Other,423210.0,
1230,1123875,1,1,,104234147,3779,Unspecified,,,,,"Inhibition of histamine-induced asthma-like syndrome in guinea pig assessed as time delay in appearance of coughing at 5 mg/kg, po treated 30 mins before histamine challenge (Rvb = 6.13 mins)",Other,423210.0,
1231,1129266,1,1,,104234147,3779,Active,,,,,Stimulation of lipolysis in mouse 3T3L1 cells at 10 uM after 48 hrs by glycerol release assay,Other,24597820.0,
1232,1134137,1,1,,104234147,3779,Unspecified,,,,,Antiallergic activity in antiovalbumin serum sensitized guinea pig lung slices assessed as inhibition of ovalbumin-induced histamine release at 0.3 uM preincubated for 5 mins followed by ovalbumin challenge measured after 15 mins by fluorometric analysis relative to control,Other,85712.0,
1233,1134667,1,1,,104234147,3779,Unspecified,,,,,Bronchodilatory activity in iv dosed mongrel dog assessed as inhibition of histamine-induced bronchospasm administered 1 min prior to histamine challenge,Other,894683.0,
1234,1134668,1,2,,104234147,3779,Unspecified,,,,,Increase in heart rate in iv dosed anesthetized mongrel dog,Other,894683.0,
1235,1136378,1,3,,104234147,3779,Unspecified,114754.0,24925.0,,,Agonist activity at beta-adrenoceptor in Sprague-Dawley rat adipocytes assessed as maximal stimulation of adenylate cyclase activity in plasmalemma measured as cAMP formation at 10'-8 M after 10 mins by scintillation counting,Other,31479.0,
1236,1136378,1,3,,104234147,3779,Unspecified,114768.0,24176.0,,,Agonist activity at beta-adrenoceptor in Sprague-Dawley rat adipocytes assessed as maximal stimulation of adenylate cyclase activity in plasmalemma measured as cAMP formation at 10'-8 M after 10 mins by scintillation counting,Other,31479.0,
1237,1136378,1,3,,104234147,3779,Unspecified,543882.0,25645.0,,,Agonist activity at beta-adrenoceptor in Sprague-Dawley rat adipocytes assessed as maximal stimulation of adenylate cyclase activity in plasmalemma measured as cAMP formation at 10'-8 M after 10 mins by scintillation counting,Other,31479.0,
1238,1136379,1,3,,104234147,3779,Unspecified,114754.0,24925.0,,,Agonist activity at beta-adrenoceptor in Sprague-Dawley rat fat cells assessed as cAMP accumulation per 10 mins at 10'-6 M,Other,31479.0,
1239,1136379,1,3,,104234147,3779,Unspecified,114768.0,24176.0,,,Agonist activity at beta-adrenoceptor in Sprague-Dawley rat fat cells assessed as cAMP accumulation per 10 mins at 10'-6 M,Other,31479.0,
1240,1136379,1,3,,104234147,3779,Unspecified,543882.0,25645.0,,,Agonist activity at beta-adrenoceptor in Sprague-Dawley rat fat cells assessed as cAMP accumulation per 10 mins at 10'-6 M,Other,31479.0,
1241,1144289,1,2,,104234147,3779,Active,,,,,Decrease in blood pressure in rat at 0.150 mg/kg,Other,1246044.0,
1242,1146002,1,1,,104234147,3779,Unspecified,,,,,Induction of magnesium accumulation in rat adipocyte plasma membrane vesicles assessed as increase of intravesicular magnesium level per 30 mins at 1 x 10'-5 M by fluorescence assay,Other,191614.0,
1243,1146003,1,1,,104234147,3779,Unspecified,,,,,Induction of magnesium accumulation in rat adipocyte plasma membrane vesicles assessed as increase of magnesium level per gram of protein per 30 mins at 1 x 10'-5 M by fluorescence assay,Other,191614.0,
1244,1146056,3,2,,104234147,3779,Active,,,0.0071,ED50,Agonist activity at beta-adrenoceptor in guinea pig trachea assessed as relaxation of spontaneously contracted tracheal smooth muscle,Confirmatory,19629.0,
1245,1146059,3,2,,104234147,3779,Active,,,,,Agonist activity at beta-adrenoceptor in guinea pig atria assessed as cardiac stimulant activity by measuring change in rate of contraction of right atrial muscle,Other,19629.0,
1246,1146065,1,2,,104234147,3779,Unspecified,,,,,Intrinsic activity at beta-adrenoceptor in guinea pig trachea assessed as relaxation of spontaneously contracted tracheal smooth muscle relative to papaverine,Other,19629.0,
1247,1146067,1,1,,104234147,3779,Unspecified,,,,,Separation ratio of ED25 at beta-adrenoceptor in guinea pig atria to ED50 for beta-adrenoceptor in guinea pig trachea,Other,19629.0,
1248,1146174,3,2,,104234147,3779,Unspecified,,,,,Agonist activity at beta-adrenergic receptor in guinea pig tracheal tissue assessed as bronchodilator activity,Other,20503.0,
1249,1146175,3,2,,104234147,3779,Unspecified,,,,,Agonist activity at beta-adrenergic receptor in guinea pig right atrial muscle assessed as rate of contraction of spontaneously beating atria,Other,20503.0,
1250,1146179,1,2,,104234147,3779,Unspecified,,,,,Selectivity ratio of ED25 for beta-adrenergic receptor in guinea pig right atrial muscle to ED50 for beta-adrenergic receptor in guinea pig tracheal tissue,Other,20503.0,
1251,1146180,3,2,,104234147,3779,Active,81914759.0,100722663.0,0.0071,ED50,Agonist activity at beta-2 adrenergic receptor in guinea pig tracheal chain assessed as relaxation of spontaneously contracted tracheal smooth muscle,Confirmatory,20504.0,
1252,1146181,3,1,,104234147,3779,Unspecified,,,,,Agonist activity at beta-1 adrenergic receptor in guinea pig right atria assessed as increase in contraction rate of spontaneously beating right atria,Other,20504.0,
1253,1146184,1,1,,104234147,3779,Unspecified,,,,,Selectivity ratio of ED25 for beta-1 adrenergic receptor in guinea pig right atria to ED50 for beta-2 adrenergic receptor in guinea pig tracheal chain,Other,20504.0,
1254,1146185,1,3,,104234147,3779,Unspecified,81914759.0,100722663.0,,,Intrinsic activity at beta-2 adrenergic receptor in guinea pig tracheal chain assessed as relaxation of spontaneously contracted tracheal smooth muscle relative to papaverine,Other,20504.0,
1255,1147939,2,1,,104234147,3779,Unspecified,,,,,"Partition coefficient, log P of the compound in CHCl3-H2O system at 4 ug/ml at pH 7.4",Other,5607.0,
1256,1148409,1,2,,104234147,3779,Unspecified,,,,ED50,Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as effect on atrial rate,Confirmatory,619150.0,
1257,1148410,1,2,,104234147,3779,Active,,,,,Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as effect on atrial rate in presence of reserpine,Other,619150.0,
1258,1148411,1,2,,104234147,3779,Unspecified,,,,ED50,Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as effect on force of atrial contraction,Confirmatory,619150.0,
1259,1148412,1,2,,104234147,3779,Active,,,,,Agonist activity at beta-1 adrenergic receptor in guinea pig atria assessed as effect on force of atrial contraction in presence of reserpine,Other,619150.0,
1260,1148417,3,2,,104234147,3779,Unspecified,81914759.0,100722663.0,,ED50,Agonist activity at beta-2 adrenergic receptor in guinea pig trachea assessed as tracheal relaxation,Confirmatory,619150.0,
1261,1148418,1,3,,104234147,3779,Unspecified,81914759.0,100722663.0,,,Agonist activity at beta-2 adrenergic receptor in guinea pig trachea assessed as tracheal relaxation in presence of reserpine,Other,619150.0,
1262,1148420,1,1,,104234147,3779,Unspecified,,,,,Ratio of relative activity for guinea pig beta-2 adrenergic receptor to relative activity for guinea pig beta-1 adrenergic receptor,Other,619150.0,
1263,1150791,1,1,,104234147,3779,Unspecified,,,,,"Bronchodilator activity in dog assessed as degree of inhibition of carbachol or histamine-induced bronchoconstriction at 0.3 to 2 mg/kg, iv relative to control",Other,950653.0,
1264,1150792,1,1,,104234147,3779,Unspecified,,,,,"Bronchodilator activity in dog assessed as degree of inhibition of carbachol or histamine-induced bronchoconstriction at 50 to 240 mg/kg, id relative to control",Other,950653.0,
1265,1150793,1,1,,104234147,3779,Unspecified,,,,,"Bronchodilator activity in dog assessed as degree of inhibition of carbachol or histamine-induced bronchoconstriction at 125 to 250 mg/kg, it relative to control",Other,950653.0,
1266,1150830,1,1,,104234147,3779,Unspecified,,,,,"Bronchodilator activity in dog assessed as time of inhibition of carbachol or histamine-induced bronchoconstriction at 0.3 to 2 mg/kg, iv relative to control",Other,950653.0,
1267,1150831,1,1,,104234147,3779,Unspecified,,,,,"Bronchodilator activity in dog assessed as time of inhibition of carbachol or histamine-induced bronchoconstriction at 50 to 240 mg/kg, id relative to control",Other,950653.0,
1268,1150832,1,1,,104234147,3779,Unspecified,,,,,"Bronchodilator activity in dog assessed as time of inhibition of carbachol or histamine-induced bronchoconstriction at 125 to 250 mg/kg, it relative to control",Other,950653.0,
1269,1150857,1,2,,104234147,3779,Unspecified,,,,,"Cardiotoxicity in spontaneously respiring dog assessed as degree of increase in heart rate at 0.3 to 2 mg/kg, iv relative to control",Other,950653.0,
1270,1150858,1,2,,104234147,3779,Unspecified,,,,,"Cardiotoxicity in spontaneously respiring dog assessed as degree of increase in heart rate at 50 to 240 mg/kg, id relative to control",Other,950653.0,
1271,1150859,1,2,,104234147,3779,Unspecified,,,,,"Cardiotoxicity in spontaneously respiring dog assessed as degree of increase in heart rate at 125 to 150 mg/kg, it relative to control",Other,950653.0,
1272,1150883,1,2,,104234147,3779,Unspecified,,,,,"Cardiotoxicity in spontaneously respiring dog assessed as time of increase in heart rate at 0.3 to 2 mg/kg, iv relative to control",Other,950653.0,
1273,1150884,1,2,,104234147,3779,Unspecified,,,,,"Cardiotoxicity in spontaneously respiring dog assessed as time of increase in heart rate at 50 to 240 mg/kg, id relative to control",Other,950653.0,
1274,1150885,1,2,,104234147,3779,Unspecified,,,,,"Cardiotoxicity in spontaneously respiring dog assessed as time of increase in heart rate at 125 to 250 mg/kg, it relative to control",Other,950653.0,
1275,1159509,1,1,,170464679,3779,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1276,1159515,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1277,1159516,1,1,,170464679,3779,Inconclusive,119611100.0,22926.0,0.5354,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1278,1159517,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1279,1159518,1,1,,170464679,3779,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1280,1159519,1,1,,170464679,3779,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1281,1159520,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1282,1159521,1,1,,170464679,3779,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1283,1159523,1,1,,170464679,3779,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1284,1159525,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1285,1159526,1,1,,170464679,3779,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1286,1159527,1,1,,170464679,3779,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1287,1159528,1,1,,170464679,3779,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1288,1159529,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1289,1159531,1,1,,170464679,3779,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1290,1159551,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1291,1159552,1,1,,170464679,3779,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1292,1159553,2,1,,170464679,3779,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1293,1159555,1,1,,170464679,3779,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1294,1159580,2,1,,268734590,3779,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1295,1159580,2,1,,273002868,3779,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1296,1159607,2,1,,312310281,3779,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1297,1159614,1,2,,170464679,3779,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1298,1190659,1,2,,104234147,3779,Active,81914759.0,100722663.0,0.02512,Kd,Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring at basal tone assessed as bronchorelaxation activity,Confirmatory,25592716.0,
1299,1190660,1,2,,104234147,3779,Active,81914759.0,100722663.0,,EC50,Agonist activity at adrenergic beta2 receptor in Hartley guinea pig tracheal ring assessed as bronchorelaxation activity against histamine-induced contraction,Confirmatory,25592716.0,
1300,1209455,1,2,,104234147,3779,Unspecified,262527527.0,8647.0,1000.0,IC50,Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
1301,1209456,1,2,,104234147,3779,Unspecified,12585136.0,83569.0,1000.0,IC50,Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake,Confirmatory,21965623.0,
1302,1209457,1,1,,104234147,3779,Active,,,,,Unbound Cmax in human plasma,Other,21965623.0,
1303,1224824,1,1,,104171176,3779,Inactive,,,7.4266,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
1304,1224825,1,1,,104171176,3779,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
1305,1224834,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1306,1224835,1,1,,170464679,3779,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1307,1224836,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1308,1224837,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1309,1224838,1,1,,170464679,3779,Inactive,66775687.0,9970.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1310,1224839,1,1,,170464679,3779,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1311,1224840,3,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1312,1224841,3,1,,170464679,3779,Inactive,325495545.0,2101.0,0.0237,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1313,1224842,3,1,,170464679,3779,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1314,1224843,1,1,,170464679,3779,Active,119601739.0,7253.0,0.0119,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1315,1224844,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1316,1224845,1,1,,170464679,3779,Inconclusive,344243002.0,100757539.0,55.1965,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1317,1224846,1,1,,170464679,3779,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1318,1224847,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1319,1224848,3,1,,170464679,3779,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1320,1224849,3,1,,170464679,3779,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1321,1224857,2,1,,104171176,3779,Inconclusive,,,0.0526,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1322,1224857,2,1,,170464679,3779,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1323,1224859,2,1,,90340610,3779,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1324,1224859,2,1,,104171176,3779,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1325,1224859,2,1,,170464679,3779,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1326,1224863,1,1,,176484013,3779,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1327,1224863,1,1,,176485053,3779,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1328,1224863,1,1,,316920374,3779,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1329,1224867,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1330,1224868,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1331,1224869,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1332,1224870,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1333,1224871,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1334,1224872,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1335,1224873,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1336,1224874,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1337,1224875,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1338,1224876,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1339,1224877,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1340,1224878,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1341,1224879,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1342,1224880,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1343,1224881,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1344,1224882,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1345,1224883,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1346,1224884,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1347,1224885,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1348,1224886,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1349,1224887,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1350,1224888,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1351,1224889,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1352,1224890,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1353,1224892,1,1,,170464679,3779,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1354,1224893,1,1,,170464679,3779,Inconclusive,66775687.0,9970.0,14.9601,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1355,1224894,1,1,,170464679,3779,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1356,1224895,1,1,,170464679,3779,Active,119601739.0,7253.0,0.007497800000000001,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1357,1224896,1,1,,170464679,3779,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1358,1224905,2,1,,92308688,3779,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1359,1224905,2,1,,92308688,3779,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1360,1238567,1,1,,104234147,3779,Active,461604.0,155.0,0.086,EC50,Agonist activity at human recombinant beta3-adrenergic receptor expressed in CHO cells assessed as increase of cAMP level after 30 mins,Confirmatory,26125514.0,
1361,1238575,1,1,,104234147,3779,Inconclusive,1168246.0,148.0,,EC50,Agonist activity at human alpha1A-adrenergic receptor expressed in HEK293 cells assessed as calcium flux by fluorescence assay,Confirmatory,26125514.0,
1362,1259241,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1363,1259242,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1364,1259243,1,1,,170464679,3779,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1365,1259244,1,1,,170464679,3779,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1366,1259247,1,1,,170464679,3779,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1367,1259248,1,1,,170464679,3779,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1368,1259252,1,1,,104171176,3779,Inconclusive,169655958.0,,7.4266,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
1369,1259253,1,1,,104171176,3779,Active,169655958.0,,5.8992,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
1370,1259255,1,1,,104171176,3779,Active,169655958.0,,20.930999999999997,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
1371,1259256,1,1,,104171176,3779,Inconclusive,169655958.0,,23.485,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
1372,1259325,1,2,,336954450,3779,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
1373,1259344,1,1,,144203723,3779,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1374,1259355,1,1,,26752240,3779,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1375,1259356,1,1,,104171176,3779,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1376,1259364,1,1,,170464679,3779,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1377,1259365,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1378,1259366,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1379,1259367,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1380,1259368,1,1,,170464679,3779,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1381,1259369,1,1,,170464679,3779,Inconclusive,109731339.0,2737.0,16.7855,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1382,1259377,1,1,,170464679,3779,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1383,1259378,1,1,,170464679,3779,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1384,1259379,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1385,1259380,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1386,1259381,1,1,,170464679,3779,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1387,1259382,1,1,,170464679,3779,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1388,1259383,1,1,,170464679,3779,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1389,1259384,1,1,,170464679,3779,Active,,,0.0021,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1390,1259385,1,1,,170464679,3779,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1391,1259386,1,1,,170464679,3779,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1392,1259387,1,1,,170464679,3779,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1393,1259388,1,1,,170464679,3779,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1394,1259390,1,1,,170464679,3779,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1395,1259391,1,1,,170464679,3779,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1396,1259392,1,1,,170464679,3779,Active,109731339.0,2737.0,5.9557199999999995,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1397,1259393,1,1,,170464679,3779,Active,119601739.0,7253.0,0.00573149,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1398,1259394,1,1,,170464679,3779,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1399,1259395,1,1,,170464679,3779,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1400,1259396,1,1,,170464679,3779,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1401,1259400,1,1,,170464679,3779,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1402,1259401,1,1,,170464679,3779,Inconclusive,325495545.0,2101.0,0.0211317,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1403,1259402,1,1,,170464679,3779,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1404,1259403,1,1,,170464679,3779,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1405,1259404,1,1,,170464679,3779,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1406,1259409,1,1,,363901031,3779,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
1407,1259410,1,1,,363901031,3779,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
1408,1259416,1,2,,340080100,3779,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
1409,1259421,1,1,,340080100,3779,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
1410,1259423,1,2,,354795388,3779,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1411,1259423,1,2,,354954491,3779,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1412,1259423,1,2,,354997979,3779,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1413,1259426,1,2,,354795388,3779,Active,550600288.0,5570400.0,0.039,EC50_MICROM,Counter Screen to Identify Specific Small molecule Agonists for Aedes aegypti NPYLR7 Receptor,Confirmatory,,
1414,1259427,1,2,,354795388,3779,Inactive,,,20.0,EC50_MICROM,Hit Validation Assay to Identify small molecule Aedes aegypti NPYLR7 Agonists [Small Molecule Inhibitors of Mosquito Biting Behavior],Confirmatory,,
